CN109851675A - A kind of aftosa diagnostic kit and its aftosa diagnostic antigen used - Google Patents
A kind of aftosa diagnostic kit and its aftosa diagnostic antigen used Download PDFInfo
- Publication number
- CN109851675A CN109851675A CN201811580365.0A CN201811580365A CN109851675A CN 109851675 A CN109851675 A CN 109851675A CN 201811580365 A CN201811580365 A CN 201811580365A CN 109851675 A CN109851675 A CN 109851675A
- Authority
- CN
- China
- Prior art keywords
- protein
- pet32a
- gly
- ala
- leu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 title claims abstract description 45
- 102000036639 antigens Human genes 0.000 title claims abstract description 45
- 108091007433 antigens Proteins 0.000 title claims abstract description 45
- 238000009007 Diagnostic Kit Methods 0.000 title abstract description 5
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 214
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 137
- 238000000034 method Methods 0.000 claims abstract description 75
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 11
- 230000009385 viral infection Effects 0.000 claims abstract description 10
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 5
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 5
- 238000002360 preparation method Methods 0.000 claims abstract description 5
- 230000004927 fusion Effects 0.000 claims abstract description 4
- 230000014509 gene expression Effects 0.000 claims description 98
- 241000710198 Foot-and-mouth disease virus Species 0.000 claims description 65
- 230000001939 inductive effect Effects 0.000 claims description 55
- 239000002773 nucleotide Substances 0.000 claims description 32
- 125000003729 nucleotide group Chemical group 0.000 claims description 32
- 241000588724 Escherichia coli Species 0.000 claims description 19
- 238000001514 detection method Methods 0.000 claims description 19
- 244000005700 microbiome Species 0.000 claims description 17
- 241000894006 Bacteria Species 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 238000005215 recombination Methods 0.000 claims description 9
- 230000006798 recombination Effects 0.000 claims description 9
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- 230000008676 import Effects 0.000 claims description 5
- 238000003259 recombinant expression Methods 0.000 claims description 5
- 241000588722 Escherichia Species 0.000 claims description 2
- 210000000003 hoof Anatomy 0.000 claims description 2
- 238000012544 monitoring process Methods 0.000 claims description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims 1
- 210000002966 serum Anatomy 0.000 abstract description 38
- 238000000746 purification Methods 0.000 abstract description 25
- 238000003149 assay kit Methods 0.000 abstract description 13
- 238000007689 inspection Methods 0.000 abstract description 4
- 230000002265 prevention Effects 0.000 abstract description 4
- 229960005486 vaccine Drugs 0.000 abstract description 3
- 230000036039 immunity Effects 0.000 abstract description 2
- 230000007246 mechanism Effects 0.000 abstract description 2
- 239000007788 liquid Substances 0.000 description 49
- 239000000243 solution Substances 0.000 description 36
- 108010077805 Bacterial Proteins Proteins 0.000 description 30
- 241001494479 Pecora Species 0.000 description 29
- 238000005457 optimization Methods 0.000 description 29
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 28
- 108020004414 DNA Proteins 0.000 description 24
- 238000012360 testing method Methods 0.000 description 24
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 22
- 239000006228 supernatant Substances 0.000 description 22
- 101710172711 Structural protein Proteins 0.000 description 20
- 239000002808 molecular sieve Substances 0.000 description 17
- 238000001556 precipitation Methods 0.000 description 17
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 17
- 229910052759 nickel Inorganic materials 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 210000003000 inclusion body Anatomy 0.000 description 12
- 239000013598 vector Substances 0.000 description 12
- 239000011780 sodium chloride Substances 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 239000007983 Tris buffer Substances 0.000 description 10
- 238000004140 cleaning Methods 0.000 description 10
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 10
- XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 8
- 239000013604 expression vector Substances 0.000 description 8
- 150000002460 imidazoles Chemical class 0.000 description 8
- 230000001376 precipitating effect Effects 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- 229910052693 Europium Inorganic materials 0.000 description 7
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 7
- 229920002684 Sepharose Polymers 0.000 description 7
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 7
- 108010028295 histidylhistidine Proteins 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- OUUCIIJSBIBCHB-ZPFDUUQYSA-N Ile-Leu-Asp Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O OUUCIIJSBIBCHB-ZPFDUUQYSA-N 0.000 description 6
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 6
- 229960000723 ampicillin Drugs 0.000 description 6
- 239000004202 carbamide Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 235000013601 eggs Nutrition 0.000 description 6
- 239000013049 sediment Substances 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- CWFMWBHMIMNZLN-NAKRPEOUSA-N (2s)-1-[(2s)-2-[[(2s,3s)-2-amino-3-methylpentanoyl]amino]propanoyl]pyrrolidine-2-carboxylic acid Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O CWFMWBHMIMNZLN-NAKRPEOUSA-N 0.000 description 5
- FJVAQLJNTSUQPY-CIUDSAMLSA-N Ala-Ala-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCCN FJVAQLJNTSUQPY-CIUDSAMLSA-N 0.000 description 5
- JBVSSSZFNTXJDX-YTLHQDLWSA-N Ala-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)N JBVSSSZFNTXJDX-YTLHQDLWSA-N 0.000 description 5
- NXSFUECZFORGOG-CIUDSAMLSA-N Ala-Asn-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O NXSFUECZFORGOG-CIUDSAMLSA-N 0.000 description 5
- KIUYPHAMDKDICO-WHFBIAKZSA-N Ala-Asp-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O KIUYPHAMDKDICO-WHFBIAKZSA-N 0.000 description 5
- GWFSQQNGMPGBEF-GHCJXIJMSA-N Ala-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)N GWFSQQNGMPGBEF-GHCJXIJMSA-N 0.000 description 5
- NBTGEURICRTMGL-WHFBIAKZSA-N Ala-Gly-Ser Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O NBTGEURICRTMGL-WHFBIAKZSA-N 0.000 description 5
- TZDNWXDLYFIFPT-BJDJZHNGSA-N Ala-Ile-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O TZDNWXDLYFIFPT-BJDJZHNGSA-N 0.000 description 5
- SOBIAADAMRHGKH-CIUDSAMLSA-N Ala-Leu-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O SOBIAADAMRHGKH-CIUDSAMLSA-N 0.000 description 5
- BTRULDJUUVGRNE-DCAQKATOSA-N Ala-Pro-Lys Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(O)=O BTRULDJUUVGRNE-DCAQKATOSA-N 0.000 description 5
- RFXXUWGNVRJTNQ-QXEWZRGKSA-N Arg-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)N RFXXUWGNVRJTNQ-QXEWZRGKSA-N 0.000 description 5
- WVNFNPGXYADPPO-BQBZGAKWSA-N Arg-Gly-Ser Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O WVNFNPGXYADPPO-BQBZGAKWSA-N 0.000 description 5
- OPEPUCYIGFEGSW-WDSKDSINSA-N Asn-Gly-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O OPEPUCYIGFEGSW-WDSKDSINSA-N 0.000 description 5
- QXHVOUSPVAWEMX-ZLUOBGJFSA-N Asp-Asp-Ser Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O QXHVOUSPVAWEMX-ZLUOBGJFSA-N 0.000 description 5
- SKSJPIBFNFPTJB-NKWVEPMBSA-N Cys-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CS)N)C(=O)O SKSJPIBFNFPTJB-NKWVEPMBSA-N 0.000 description 5
- LBSKYJOZIIOZIO-DCAQKATOSA-N Cys-Lys-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CS)N LBSKYJOZIIOZIO-DCAQKATOSA-N 0.000 description 5
- ZWABFSSWTSAMQN-KBIXCLLPSA-N Glu-Ile-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O ZWABFSSWTSAMQN-KBIXCLLPSA-N 0.000 description 5
- HZISRJBYZAODRV-XQXXSGGOSA-N Glu-Thr-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O HZISRJBYZAODRV-XQXXSGGOSA-N 0.000 description 5
- QGAJQIGFFIQJJK-IHRRRGAJSA-N Glu-Tyr-Gln Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)N)O QGAJQIGFFIQJJK-IHRRRGAJSA-N 0.000 description 5
- MHXKHKWHPNETGG-QWRGUYRKSA-N Gly-Lys-Leu Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O MHXKHKWHPNETGG-QWRGUYRKSA-N 0.000 description 5
- ZWRDOVYMQAAISL-UWVGGRQHSA-N Gly-Met-Lys Chemical compound CSCC[C@H](NC(=O)CN)C(=O)N[C@H](C(O)=O)CCCCN ZWRDOVYMQAAISL-UWVGGRQHSA-N 0.000 description 5
- BZKDJRSZWLPJNI-SRVKXCTJSA-N His-His-Ser Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(O)=O BZKDJRSZWLPJNI-SRVKXCTJSA-N 0.000 description 5
- LVWIJITYHRZHBO-IXOXFDKPSA-N His-Leu-Thr Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LVWIJITYHRZHBO-IXOXFDKPSA-N 0.000 description 5
- XDIVYNSPYBLSME-DCAQKATOSA-N His-Met-Asp Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N XDIVYNSPYBLSME-DCAQKATOSA-N 0.000 description 5
- UDLAWRKOVFDKFL-PEFMBERDSA-N Ile-Asp-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N UDLAWRKOVFDKFL-PEFMBERDSA-N 0.000 description 5
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 5
- HYMLKESRWLZDBR-WEDXCCLWSA-N Leu-Gly-Thr Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O HYMLKESRWLZDBR-WEDXCCLWSA-N 0.000 description 5
- HVHRPWQEQHIQJF-AVGNSLFASA-N Leu-Lys-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O HVHRPWQEQHIQJF-AVGNSLFASA-N 0.000 description 5
- PJWOOBTYQNNRBF-BZSNNMDCSA-N Leu-Phe-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)O)N PJWOOBTYQNNRBF-BZSNNMDCSA-N 0.000 description 5
- WQWZXKWOEVSGQM-DCAQKATOSA-N Lys-Ala-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN WQWZXKWOEVSGQM-DCAQKATOSA-N 0.000 description 5
- XNKDCYABMBBEKN-IUCAKERBSA-N Lys-Gly-Gln Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(N)=O XNKDCYABMBBEKN-IUCAKERBSA-N 0.000 description 5
- JYXBNQOKPRQNQS-YTFOTSKYSA-N Lys-Ile-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JYXBNQOKPRQNQS-YTFOTSKYSA-N 0.000 description 5
- NJNRBRKHOWSGMN-SRVKXCTJSA-N Lys-Leu-Asn Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O NJNRBRKHOWSGMN-SRVKXCTJSA-N 0.000 description 5
- VKCPHIOZDWUFSW-ONGXEEELSA-N Lys-Val-Gly Chemical compound OC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN VKCPHIOZDWUFSW-ONGXEEELSA-N 0.000 description 5
- RXWPLVRJQNWXRQ-IHRRRGAJSA-N Met-His-His Chemical compound C([C@H](NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)C1=CNC=N1 RXWPLVRJQNWXRQ-IHRRRGAJSA-N 0.000 description 5
- RDLSEGZJMYGFNS-FXQIFTODSA-N Met-Ser-Asp Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O RDLSEGZJMYGFNS-FXQIFTODSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 5
- SWZKMTDPQXLQRD-XVSYOHENSA-N Phe-Asp-Thr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SWZKMTDPQXLQRD-XVSYOHENSA-N 0.000 description 5
- HOYQLNNGMHXZDW-KKUMJFAQSA-N Phe-Glu-Arg Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O HOYQLNNGMHXZDW-KKUMJFAQSA-N 0.000 description 5
- YKUGPVXSDOOANW-KKUMJFAQSA-N Phe-Leu-Asp Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O YKUGPVXSDOOANW-KKUMJFAQSA-N 0.000 description 5
- AFXCXDQNRXTSBD-FJXKBIBVSA-N Pro-Gly-Thr Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O AFXCXDQNRXTSBD-FJXKBIBVSA-N 0.000 description 5
- FDMCIBSQRKFSTJ-RHYQMDGZSA-N Pro-Thr-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O FDMCIBSQRKFSTJ-RHYQMDGZSA-N 0.000 description 5
- DLZBBDSPTJBOOD-BPNCWPANSA-N Pro-Tyr-Ala Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(O)=O DLZBBDSPTJBOOD-BPNCWPANSA-N 0.000 description 5
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
- IXCHOHLPHNGFTJ-YUMQZZPRSA-N Ser-Gly-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CO)N IXCHOHLPHNGFTJ-YUMQZZPRSA-N 0.000 description 5
- GZFAWAQTEYDKII-YUMQZZPRSA-N Ser-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CO GZFAWAQTEYDKII-YUMQZZPRSA-N 0.000 description 5
- PJIQEIFXZPCWOJ-FXQIFTODSA-N Ser-Pro-Asp Chemical compound [H]N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O PJIQEIFXZPCWOJ-FXQIFTODSA-N 0.000 description 5
- OGOYMQWIWHGTGH-KZVJFYERSA-N Thr-Val-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O OGOYMQWIWHGTGH-KZVJFYERSA-N 0.000 description 5
- MQVGIFJSFFVGFW-XEGUGMAKSA-N Trp-Ala-Glu Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O MQVGIFJSFFVGFW-XEGUGMAKSA-N 0.000 description 5
- FNWGDMZVYBVAGJ-XEGUGMAKSA-N Tyr-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC1=CC=C(C=C1)O)N FNWGDMZVYBVAGJ-XEGUGMAKSA-N 0.000 description 5
- HHSILIQTHXABKM-YDHLFZDLSA-N Val-Asp-Phe Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(O)=O HHSILIQTHXABKM-YDHLFZDLSA-N 0.000 description 5
- AEMPCGRFEZTWIF-IHRRRGAJSA-N Val-Leu-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O AEMPCGRFEZTWIF-IHRRRGAJSA-N 0.000 description 5
- 108010024078 alanyl-glycyl-serine Proteins 0.000 description 5
- 108010008355 arginyl-glutamine Proteins 0.000 description 5
- 108010069926 arginyl-glycyl-serine Proteins 0.000 description 5
- 108010038633 aspartylglutamate Proteins 0.000 description 5
- 108010092854 aspartyllysine Proteins 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 108010078144 glutaminyl-glycine Proteins 0.000 description 5
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 5
- 108010000434 glycyl-alanyl-leucine Proteins 0.000 description 5
- 108010001064 glycyl-glycyl-glycyl-glycine Proteins 0.000 description 5
- 108010077515 glycylproline Proteins 0.000 description 5
- 108010009298 lysylglutamic acid Proteins 0.000 description 5
- 108010038320 lysylphenylalanine Proteins 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000009465 prokaryotic expression Effects 0.000 description 5
- 108010053725 prolylvaline Proteins 0.000 description 5
- 108010060175 trypsinogen activation peptide Proteins 0.000 description 5
- 108010005834 tyrosyl-alanyl-glycine Proteins 0.000 description 5
- CKLDHDOIYBVUNP-KBIXCLLPSA-N Ala-Ile-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(O)=O CKLDHDOIYBVUNP-KBIXCLLPSA-N 0.000 description 4
- 101150010856 CRT gene Proteins 0.000 description 4
- GLEGHWQNGPMKHO-DCAQKATOSA-N Gln-His-Glu Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CCC(=O)N)N GLEGHWQNGPMKHO-DCAQKATOSA-N 0.000 description 4
- VSRCAOIHMGCIJK-SRVKXCTJSA-N Glu-Leu-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O VSRCAOIHMGCIJK-SRVKXCTJSA-N 0.000 description 4
- OCJRHJZKGGSPRW-IUCAKERBSA-N Glu-Lys-Gly Chemical compound NCCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O OCJRHJZKGGSPRW-IUCAKERBSA-N 0.000 description 4
- FJWSJWACLMTDMI-WPRPVWTQSA-N Gly-Met-Val Chemical compound [H]NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(O)=O FJWSJWACLMTDMI-WPRPVWTQSA-N 0.000 description 4
- VNNRLUNBJSWZPF-ZKWXMUAHSA-N Gly-Ser-Ile Chemical compound [H]NCC(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VNNRLUNBJSWZPF-ZKWXMUAHSA-N 0.000 description 4
- ZZLWLWSUIBSMNP-CIUDSAMLSA-N His-Asp-Ser Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O ZZLWLWSUIBSMNP-CIUDSAMLSA-N 0.000 description 4
- ADDYYRVQQZFIMW-MNXVOIDGSA-N Ile-Lys-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N ADDYYRVQQZFIMW-MNXVOIDGSA-N 0.000 description 4
- 108010065920 Insulin Lispro Proteins 0.000 description 4
- IBMVEYRWAWIOTN-UHFFFAOYSA-N L-Leucyl-L-Arginyl-L-Proline Natural products CC(C)CC(N)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(O)=O IBMVEYRWAWIOTN-UHFFFAOYSA-N 0.000 description 4
- KZRQONDKKJCAOL-DKIMLUQUSA-N Phe-Leu-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KZRQONDKKJCAOL-DKIMLUQUSA-N 0.000 description 4
- RYQWALWYQWBUKN-FHWLQOOXSA-N Phe-Phe-Glu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O RYQWALWYQWBUKN-FHWLQOOXSA-N 0.000 description 4
- VMVNCJDKFOQOHM-GUBZILKMSA-N Ser-Gln-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)N VMVNCJDKFOQOHM-GUBZILKMSA-N 0.000 description 4
- MOINZPRHJGTCHZ-MMWGEVLESA-N Ser-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CO)N MOINZPRHJGTCHZ-MMWGEVLESA-N 0.000 description 4
- RWOGENDAOGMHLX-DCAQKATOSA-N Val-Lys-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)N RWOGENDAOGMHLX-DCAQKATOSA-N 0.000 description 4
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 108010049041 glutamylalanine Proteins 0.000 description 4
- 108010031719 prolyl-serine Proteins 0.000 description 4
- 238000004153 renaturation Methods 0.000 description 4
- MDNAVFBZPROEHO-UHFFFAOYSA-N Ala-Lys-Val Natural products CC(C)C(C(O)=O)NC(=O)C(NC(=O)C(C)N)CCCCN MDNAVFBZPROEHO-UHFFFAOYSA-N 0.000 description 3
- OBFTYSPXDRROQO-SRVKXCTJSA-N Arg-Gln-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCN=C(N)N OBFTYSPXDRROQO-SRVKXCTJSA-N 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 241000193468 Clostridium perfringens Species 0.000 description 3
- RCCDHXSRMWCOOY-GUBZILKMSA-N Glu-Arg-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(O)=O RCCDHXSRMWCOOY-GUBZILKMSA-N 0.000 description 3
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 3
- OZVXDDFYCQOPFD-XQQFMLRXSA-N Lys-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCCN)N OZVXDDFYCQOPFD-XQQFMLRXSA-N 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- MRYUJHGPZQNOAD-IHRRRGAJSA-N Pro-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@@H]1CCCN1 MRYUJHGPZQNOAD-IHRRRGAJSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 108010005233 alanylglutamic acid Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000005336 cracking Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 239000004744 fabric Substances 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 238000005374 membrane filtration Methods 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- 125000003835 nucleoside group Chemical group 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 230000009182 swimming Effects 0.000 description 3
- QMOQBVOBWVNSNO-UHFFFAOYSA-N 2-[[2-[[2-[(2-azaniumylacetyl)amino]acetyl]amino]acetyl]amino]acetate Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(O)=O QMOQBVOBWVNSNO-UHFFFAOYSA-N 0.000 description 2
- LWUWMHIOBPTZBA-DCAQKATOSA-N Ala-Arg-Lys Chemical compound NC(=N)NCCC[C@H](NC(=O)[C@@H](N)C)C(=O)N[C@@H](CCCCN)C(O)=O LWUWMHIOBPTZBA-DCAQKATOSA-N 0.000 description 2
- VBRDBGCROKWTPV-XHNCKOQMSA-N Ala-Glu-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N VBRDBGCROKWTPV-XHNCKOQMSA-N 0.000 description 2
- WEZNQZHACPSMEF-QEJZJMRPSA-N Ala-Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=CC=C1 WEZNQZHACPSMEF-QEJZJMRPSA-N 0.000 description 2
- VHAQSYHSDKERBS-XPUUQOCRSA-N Ala-Val-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O VHAQSYHSDKERBS-XPUUQOCRSA-N 0.000 description 2
- 208000031295 Animal disease Diseases 0.000 description 2
- MUXONAMCEUBVGA-DCAQKATOSA-N Arg-Arg-Gln Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(O)=O MUXONAMCEUBVGA-DCAQKATOSA-N 0.000 description 2
- MZRBYBIQTIKERR-GUBZILKMSA-N Arg-Glu-Gln Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O MZRBYBIQTIKERR-GUBZILKMSA-N 0.000 description 2
- UZGFHWIJWPUPOH-IHRRRGAJSA-N Arg-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N UZGFHWIJWPUPOH-IHRRRGAJSA-N 0.000 description 2
- NMRHDSAOIURTNT-RWMBFGLXSA-N Arg-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N NMRHDSAOIURTNT-RWMBFGLXSA-N 0.000 description 2
- YCYXHLZRUSJITQ-SRVKXCTJSA-N Arg-Pro-Pro Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 YCYXHLZRUSJITQ-SRVKXCTJSA-N 0.000 description 2
- KDFQZBWWPYQBEN-ZLUOBGJFSA-N Asp-Ala-Asn Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)O)N KDFQZBWWPYQBEN-ZLUOBGJFSA-N 0.000 description 2
- XEDQMTWEYFBOIK-ACZMJKKPSA-N Asp-Ala-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O XEDQMTWEYFBOIK-ACZMJKKPSA-N 0.000 description 2
- YFGUZQQCSDZRBN-DCAQKATOSA-N Asp-Pro-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O YFGUZQQCSDZRBN-DCAQKATOSA-N 0.000 description 2
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 description 2
- XFKUFUJECJUQTQ-CIUDSAMLSA-N Gln-Gln-Glu Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O XFKUFUJECJUQTQ-CIUDSAMLSA-N 0.000 description 2
- ARYKRXHBIPLULY-XKBZYTNZSA-N Gln-Thr-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O ARYKRXHBIPLULY-XKBZYTNZSA-N 0.000 description 2
- SBYVDRJAXWSXQL-AVGNSLFASA-N Glu-Asn-Phe Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O SBYVDRJAXWSXQL-AVGNSLFASA-N 0.000 description 2
- OPAINBJQDQTGJY-JGVFFNPUSA-N Glu-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CCC(=O)O)N)C(=O)O OPAINBJQDQTGJY-JGVFFNPUSA-N 0.000 description 2
- IRXNJYPKBVERCW-DCAQKATOSA-N Glu-Leu-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O IRXNJYPKBVERCW-DCAQKATOSA-N 0.000 description 2
- LJPIRKICOISLKN-WHFBIAKZSA-N Gly-Ala-Ser Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O LJPIRKICOISLKN-WHFBIAKZSA-N 0.000 description 2
- XBWMTPAIUQIWKA-BYULHYEWSA-N Gly-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CN XBWMTPAIUQIWKA-BYULHYEWSA-N 0.000 description 2
- HFPVRZWORNJRRC-UWVGGRQHSA-N Gly-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)CN HFPVRZWORNJRRC-UWVGGRQHSA-N 0.000 description 2
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 2
- CDGLBYSAZFIIJO-RCOVLWMOSA-N Ile-Gly-Gly Chemical compound CC[C@H](C)[C@H]([NH3+])C(=O)NCC(=O)NCC([O-])=O CDGLBYSAZFIIJO-RCOVLWMOSA-N 0.000 description 2
- GRZSCTXVCDUIPO-SRVKXCTJSA-N Leu-Arg-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(O)=O GRZSCTXVCDUIPO-SRVKXCTJSA-N 0.000 description 2
- DZQMXBALGUHGJT-GUBZILKMSA-N Leu-Glu-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O DZQMXBALGUHGJT-GUBZILKMSA-N 0.000 description 2
- IWTBYNQNAPECCS-AVGNSLFASA-N Leu-Glu-His Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 IWTBYNQNAPECCS-AVGNSLFASA-N 0.000 description 2
- YEIYAQQKADPIBJ-GARJFASQSA-N Lys-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCCN)N)C(=O)O YEIYAQQKADPIBJ-GARJFASQSA-N 0.000 description 2
- HYSVGEAWTGPMOA-IHRRRGAJSA-N Lys-Pro-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O HYSVGEAWTGPMOA-IHRRRGAJSA-N 0.000 description 2
- NYTDJEZBAAFLLG-IHRRRGAJSA-N Lys-Val-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(O)=O NYTDJEZBAAFLLG-IHRRRGAJSA-N 0.000 description 2
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 2
- 208000007634 Peste-des-Petits-Ruminants Diseases 0.000 description 2
- MPGJIHFJCXTVEX-KKUMJFAQSA-N Phe-Arg-Glu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O MPGJIHFJCXTVEX-KKUMJFAQSA-N 0.000 description 2
- KUSYCSMTTHSZOA-DZKIICNBSA-N Phe-Val-Gln Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N KUSYCSMTTHSZOA-DZKIICNBSA-N 0.000 description 2
- NHDVNAKDACFHPX-GUBZILKMSA-N Pro-Arg-Ala Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O NHDVNAKDACFHPX-GUBZILKMSA-N 0.000 description 2
- HFNPOYOKIPGAEI-SRVKXCTJSA-N Pro-Leu-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1 HFNPOYOKIPGAEI-SRVKXCTJSA-N 0.000 description 2
- BRJGUPWVFXKBQI-XUXIUFHCSA-N Pro-Leu-Ile Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O BRJGUPWVFXKBQI-XUXIUFHCSA-N 0.000 description 2
- XZBYTHCRAVAXQQ-DCAQKATOSA-N Pro-Met-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(O)=O XZBYTHCRAVAXQQ-DCAQKATOSA-N 0.000 description 2
- 101800001090 Protein 3A Proteins 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- UKKROEYWYIHWBD-ZKWXMUAHSA-N Ser-Val-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O UKKROEYWYIHWBD-ZKWXMUAHSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- DHPPWTOLRWYIDS-XKBZYTNZSA-N Thr-Cys-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(O)=O DHPPWTOLRWYIDS-XKBZYTNZSA-N 0.000 description 2
- GKWNLDNXMMLRMC-GLLZPBPUSA-N Thr-Glu-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N)O GKWNLDNXMMLRMC-GLLZPBPUSA-N 0.000 description 2
- RFKVQLIXNVEOMB-WEDXCCLWSA-N Thr-Leu-Gly Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)O)N)O RFKVQLIXNVEOMB-WEDXCCLWSA-N 0.000 description 2
- UMPVMAYCLYMYGA-ONGXEEELSA-N Val-Leu-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O UMPVMAYCLYMYGA-ONGXEEELSA-N 0.000 description 2
- IJGPOONOTBNTFS-GVXVVHGQSA-N Val-Lys-Glu Chemical compound [H]N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O IJGPOONOTBNTFS-GVXVVHGQSA-N 0.000 description 2
- 108010001271 arginyl-glutamyl-arginine Proteins 0.000 description 2
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 108010006664 gamma-glutamyl-glycyl-glycine Proteins 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 108010080575 glutamyl-aspartyl-alanine Proteins 0.000 description 2
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 2
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 2
- 108010081551 glycylphenylalanine Proteins 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 108010034529 leucyl-lysine Proteins 0.000 description 2
- 108010017391 lysylvaline Proteins 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 208000030194 mouth disease Diseases 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 108010090894 prolylleucine Proteins 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 229910052761 rare earth metal Inorganic materials 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- IGXNPQWXIRIGBF-KEOOTSPTSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidazol-5-yl)propanoic acid Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 IGXNPQWXIRIGBF-KEOOTSPTSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- JEPNLGMEZMCFEX-QSFUFRPTSA-N Ala-His-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](C)N JEPNLGMEZMCFEX-QSFUFRPTSA-N 0.000 description 1
- FOHXUHGZZKETFI-JBDRJPRFSA-N Ala-Ile-Cys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](C)N FOHXUHGZZKETFI-JBDRJPRFSA-N 0.000 description 1
- OPZJWMJPCNNZNT-DCAQKATOSA-N Ala-Leu-Met Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)O)N OPZJWMJPCNNZNT-DCAQKATOSA-N 0.000 description 1
- MEFILNJXAVSUTO-JXUBOQSCSA-N Ala-Leu-Thr Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MEFILNJXAVSUTO-JXUBOQSCSA-N 0.000 description 1
- AJBVYEYZVYPFCF-CIUDSAMLSA-N Ala-Lys-Asn Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O AJBVYEYZVYPFCF-CIUDSAMLSA-N 0.000 description 1
- WQKAQKZRDIZYNV-VZFHVOOUSA-N Ala-Ser-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O WQKAQKZRDIZYNV-VZFHVOOUSA-N 0.000 description 1
- MTDDMSUUXNQMKK-BPNCWPANSA-N Ala-Tyr-Arg Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N MTDDMSUUXNQMKK-BPNCWPANSA-N 0.000 description 1
- 102100034613 Annexin A2 Human genes 0.000 description 1
- 108090000668 Annexin A2 Proteins 0.000 description 1
- PNIGSVZJNVUVJA-BQBZGAKWSA-N Arg-Gly-Asn Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O PNIGSVZJNVUVJA-BQBZGAKWSA-N 0.000 description 1
- NYDIVDKTULRINZ-AVGNSLFASA-N Arg-Met-Lys Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N NYDIVDKTULRINZ-AVGNSLFASA-N 0.000 description 1
- ISVACHFCVRKIDG-SRVKXCTJSA-N Arg-Val-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O ISVACHFCVRKIDG-SRVKXCTJSA-N 0.000 description 1
- RZVVKNIACROXRM-ZLUOBGJFSA-N Asn-Ala-Asp Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CC(=O)N)N RZVVKNIACROXRM-ZLUOBGJFSA-N 0.000 description 1
- PUUPMDXIHCOPJU-HJGDQZAQSA-N Asn-Thr-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N)O PUUPMDXIHCOPJU-HJGDQZAQSA-N 0.000 description 1
- DTNUIAJCPRMNBT-WHFBIAKZSA-N Asp-Gly-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(O)=O DTNUIAJCPRMNBT-WHFBIAKZSA-N 0.000 description 1
- SPWXXPFDTMYTRI-IUKAMOBKSA-N Asp-Ile-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SPWXXPFDTMYTRI-IUKAMOBKSA-N 0.000 description 1
- AHWRSSLYSGLBGD-CIUDSAMLSA-N Asp-Pro-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O AHWRSSLYSGLBGD-CIUDSAMLSA-N 0.000 description 1
- CUQDCPXNZPDYFQ-ZLUOBGJFSA-N Asp-Ser-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O CUQDCPXNZPDYFQ-ZLUOBGJFSA-N 0.000 description 1
- UEFODXNXUAVPTC-VEVYYDQMSA-N Asp-Thr-Met Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CC(=O)O)N)O UEFODXNXUAVPTC-VEVYYDQMSA-N 0.000 description 1
- XWKBWZXGNXTDKY-ZKWXMUAHSA-N Asp-Val-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC(O)=O XWKBWZXGNXTDKY-ZKWXMUAHSA-N 0.000 description 1
- YFXFOZPXVFPBDH-VZFHVOOUSA-N Cys-Ala-Thr Chemical compound C[C@@H](O)[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](N)CS)C(O)=O YFXFOZPXVFPBDH-VZFHVOOUSA-N 0.000 description 1
- BCWIFCLVCRAIQK-ZLUOBGJFSA-N Cys-Ser-Cys Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CS)N)O BCWIFCLVCRAIQK-ZLUOBGJFSA-N 0.000 description 1
- 229910052692 Dysprosium Inorganic materials 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- SOIAHPSKKUYREP-CIUDSAMLSA-N Gln-Asp-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)N SOIAHPSKKUYREP-CIUDSAMLSA-N 0.000 description 1
- KCJJFESQRXGTGC-BQBZGAKWSA-N Gln-Glu-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O KCJJFESQRXGTGC-BQBZGAKWSA-N 0.000 description 1
- WEAVZFWWIPIANL-SRVKXCTJSA-N Gln-Lys-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)N)N WEAVZFWWIPIANL-SRVKXCTJSA-N 0.000 description 1
- XTZDZAXYPDISRR-MNXVOIDGSA-N Glu-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N XTZDZAXYPDISRR-MNXVOIDGSA-N 0.000 description 1
- AQNYKMCFCCZEEL-JYJNAYRXSA-N Glu-Lys-Tyr Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 AQNYKMCFCCZEEL-JYJNAYRXSA-N 0.000 description 1
- CQGBSALYGOXQPE-HTUGSXCWSA-N Glu-Thr-Phe Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CCC(=O)O)N)O CQGBSALYGOXQPE-HTUGSXCWSA-N 0.000 description 1
- QXPRJQPCFXMCIY-NKWVEPMBSA-N Gly-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN QXPRJQPCFXMCIY-NKWVEPMBSA-N 0.000 description 1
- GGEJHJIXRBTJPD-BYPYZUCNSA-N Gly-Asn-Gly Chemical compound NCC(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O GGEJHJIXRBTJPD-BYPYZUCNSA-N 0.000 description 1
- HMHRTKOWRUPPNU-RCOVLWMOSA-N Gly-Ile-Gly Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(O)=O HMHRTKOWRUPPNU-RCOVLWMOSA-N 0.000 description 1
- TVUWMSBGMVAHSJ-KBPBESRZSA-N Gly-Leu-Phe Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 TVUWMSBGMVAHSJ-KBPBESRZSA-N 0.000 description 1
- FXGRXIATVXUAHO-WEDXCCLWSA-N Gly-Lys-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCCN FXGRXIATVXUAHO-WEDXCCLWSA-N 0.000 description 1
- OCPPBNKYGYSLOE-IUCAKERBSA-N Gly-Pro-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)CN OCPPBNKYGYSLOE-IUCAKERBSA-N 0.000 description 1
- JNGHLWWFPGIJER-STQMWFEESA-N Gly-Pro-Tyr Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 JNGHLWWFPGIJER-STQMWFEESA-N 0.000 description 1
- FFJQHWKSGAWSTJ-BFHQHQDPSA-N Gly-Thr-Ala Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O FFJQHWKSGAWSTJ-BFHQHQDPSA-N 0.000 description 1
- BNMRSWQOHIQTFL-JSGCOSHPSA-N Gly-Val-Phe Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 BNMRSWQOHIQTFL-JSGCOSHPSA-N 0.000 description 1
- STOOMQFEJUVAKR-KKUMJFAQSA-N His-His-His Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)C1=CNC=N1 STOOMQFEJUVAKR-KKUMJFAQSA-N 0.000 description 1
- AYUOWUNWZGTNKB-ULQDDVLXSA-N His-Phe-Arg Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O AYUOWUNWZGTNKB-ULQDDVLXSA-N 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- UAQSZXGJGLHMNV-XEGUGMAKSA-N Ile-Gly-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N UAQSZXGJGLHMNV-XEGUGMAKSA-N 0.000 description 1
- KXUKTDGKLAOCQK-LSJOCFKGSA-N Ile-Val-Gly Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O KXUKTDGKLAOCQK-LSJOCFKGSA-N 0.000 description 1
- SITWEMZOJNKJCH-UHFFFAOYSA-N L-alanine-L-arginine Natural products CC(N)C(=O)NC(C(O)=O)CCCNC(N)=N SITWEMZOJNKJCH-UHFFFAOYSA-N 0.000 description 1
- KWTVLKBOQATPHJ-SRVKXCTJSA-N Leu-Ala-Lys Chemical compound C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(C)C)N KWTVLKBOQATPHJ-SRVKXCTJSA-N 0.000 description 1
- ULXYQAJWJGLCNR-YUMQZZPRSA-N Leu-Asp-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O ULXYQAJWJGLCNR-YUMQZZPRSA-N 0.000 description 1
- QLDHBYRUNQZIJQ-DKIMLUQUSA-N Leu-Ile-Phe Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O QLDHBYRUNQZIJQ-DKIMLUQUSA-N 0.000 description 1
- JKSIBWITFMQTOA-XUXIUFHCSA-N Leu-Ile-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O JKSIBWITFMQTOA-XUXIUFHCSA-N 0.000 description 1
- LZHJZLHSRGWBBE-IHRRRGAJSA-N Leu-Lys-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O LZHJZLHSRGWBBE-IHRRRGAJSA-N 0.000 description 1
- ZDBMWELMUCLUPL-QEJZJMRPSA-N Leu-Phe-Ala Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C)C(O)=O)CC1=CC=CC=C1 ZDBMWELMUCLUPL-QEJZJMRPSA-N 0.000 description 1
- XWEVVRRSIOBJOO-SRVKXCTJSA-N Leu-Pro-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O XWEVVRRSIOBJOO-SRVKXCTJSA-N 0.000 description 1
- IZPVWNSAVUQBGP-CIUDSAMLSA-N Leu-Ser-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O IZPVWNSAVUQBGP-CIUDSAMLSA-N 0.000 description 1
- HGLKOTPFWOMPOB-MEYUZBJRSA-N Leu-Thr-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HGLKOTPFWOMPOB-MEYUZBJRSA-N 0.000 description 1
- RVOMPSJXSRPFJT-DCAQKATOSA-N Lys-Ala-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O RVOMPSJXSRPFJT-DCAQKATOSA-N 0.000 description 1
- XFIHDSBIPWEYJJ-YUMQZZPRSA-N Lys-Ala-Gly Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN XFIHDSBIPWEYJJ-YUMQZZPRSA-N 0.000 description 1
- WGCKDDHUFPQSMZ-ZPFDUUQYSA-N Lys-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CCCCN WGCKDDHUFPQSMZ-ZPFDUUQYSA-N 0.000 description 1
- CANPXOLVTMKURR-WEDXCCLWSA-N Lys-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN CANPXOLVTMKURR-WEDXCCLWSA-N 0.000 description 1
- CBNMHRCLYBJIIZ-XUXIUFHCSA-N Lys-Ile-Met Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CCCCN)N CBNMHRCLYBJIIZ-XUXIUFHCSA-N 0.000 description 1
- MTBLFIQZECOEBY-IHRRRGAJSA-N Lys-Met-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(O)=O MTBLFIQZECOEBY-IHRRRGAJSA-N 0.000 description 1
- FJVJLMZUIGMFFU-BQBZGAKWSA-N Met-Asp-Gly Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O FJVJLMZUIGMFFU-BQBZGAKWSA-N 0.000 description 1
- LBNFTWKGISQVEE-AVGNSLFASA-N Met-Leu-Met Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCSC LBNFTWKGISQVEE-AVGNSLFASA-N 0.000 description 1
- WYBVBIHNJWOLCJ-UHFFFAOYSA-N N-L-arginyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCCN=C(N)N WYBVBIHNJWOLCJ-UHFFFAOYSA-N 0.000 description 1
- 101800000440 Non-structural protein NS3A Proteins 0.000 description 1
- OYQBFWWQSVIHBN-FHWLQOOXSA-N Phe-Glu-Phe Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O OYQBFWWQSVIHBN-FHWLQOOXSA-N 0.000 description 1
- QBFONMUYNSNKIX-AVGNSLFASA-N Pro-Arg-His Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O QBFONMUYNSNKIX-AVGNSLFASA-N 0.000 description 1
- HAAQQNHQZBOWFO-LURJTMIESA-N Pro-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1 HAAQQNHQZBOWFO-LURJTMIESA-N 0.000 description 1
- JUJGNDZIKKQMDJ-IHRRRGAJSA-N Pro-His-His Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CNC=N1)C(O)=O JUJGNDZIKKQMDJ-IHRRRGAJSA-N 0.000 description 1
- XDKKMRPRRCOELJ-GUBZILKMSA-N Pro-Val-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CCCN1 XDKKMRPRRCOELJ-GUBZILKMSA-N 0.000 description 1
- IMNVAOPEMFDAQD-NHCYSSNCSA-N Pro-Val-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O IMNVAOPEMFDAQD-NHCYSSNCSA-N 0.000 description 1
- FHJQROWZEJFZPO-SRVKXCTJSA-N Pro-Val-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CCCN1 FHJQROWZEJFZPO-SRVKXCTJSA-N 0.000 description 1
- 108010079005 RDV peptide Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
- 229910052772 Samarium Inorganic materials 0.000 description 1
- BTKUIVBNGBFTTP-WHFBIAKZSA-N Ser-Ala-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)NCC(O)=O BTKUIVBNGBFTTP-WHFBIAKZSA-N 0.000 description 1
- MIJWOJAXARLEHA-WDSKDSINSA-N Ser-Gly-Glu Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(O)=O MIJWOJAXARLEHA-WDSKDSINSA-N 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- 241001493546 Suina Species 0.000 description 1
- 229910052771 Terbium Inorganic materials 0.000 description 1
- NLSNVZAREYQMGR-HJGDQZAQSA-N Thr-Asp-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O NLSNVZAREYQMGR-HJGDQZAQSA-N 0.000 description 1
- ONNSECRQFSTMCC-XKBZYTNZSA-N Thr-Glu-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O ONNSECRQFSTMCC-XKBZYTNZSA-N 0.000 description 1
- DLZKEQQWXODGGZ-KWQFWETISA-N Tyr-Ala-Gly Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 DLZKEQQWXODGGZ-KWQFWETISA-N 0.000 description 1
- QYSBJAUCUKHSLU-JYJNAYRXSA-N Tyr-Arg-Val Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(O)=O QYSBJAUCUKHSLU-JYJNAYRXSA-N 0.000 description 1
- FQNUWOHNGJWNLM-QWRGUYRKSA-N Tyr-Cys-Gly Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CS)C(=O)NCC(O)=O FQNUWOHNGJWNLM-QWRGUYRKSA-N 0.000 description 1
- CDKZJGMPZHPAJC-ULQDDVLXSA-N Tyr-Leu-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 CDKZJGMPZHPAJC-ULQDDVLXSA-N 0.000 description 1
- JTWIMNMUYLQNPI-WPRPVWTQSA-N Val-Gly-Arg Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCNC(N)=N JTWIMNMUYLQNPI-WPRPVWTQSA-N 0.000 description 1
- BZMIYHIJVVJPCK-QSFUFRPTSA-N Val-Ile-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](C(C)C)N BZMIYHIJVVJPCK-QSFUFRPTSA-N 0.000 description 1
- XTDDIVQWDXMRJL-IHRRRGAJSA-N Val-Leu-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](C(C)C)N XTDDIVQWDXMRJL-IHRRRGAJSA-N 0.000 description 1
- DIOSYUIWOQCXNR-ONGXEEELSA-N Val-Lys-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O DIOSYUIWOQCXNR-ONGXEEELSA-N 0.000 description 1
- YMTOEGGOCHVGEH-IHRRRGAJSA-N Val-Lys-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O YMTOEGGOCHVGEH-IHRRRGAJSA-N 0.000 description 1
- JVGHIFMSFBZDHH-WPRPVWTQSA-N Val-Met-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)O)N JVGHIFMSFBZDHH-WPRPVWTQSA-N 0.000 description 1
- AJNUKMZFHXUBMK-GUBZILKMSA-N Val-Ser-Arg Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N AJNUKMZFHXUBMK-GUBZILKMSA-N 0.000 description 1
- ZHWZDZFWBXWPDW-GUBZILKMSA-N Val-Val-Cys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(O)=O ZHWZDZFWBXWPDW-GUBZILKMSA-N 0.000 description 1
- AOILQMZPNLUXCM-AVGNSLFASA-N Val-Val-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN AOILQMZPNLUXCM-AVGNSLFASA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 108010076324 alanyl-glycyl-glycine Proteins 0.000 description 1
- 108010070783 alanyltyrosine Proteins 0.000 description 1
- 238000005267 amalgamation Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 108010047857 aspartylglycine Proteins 0.000 description 1
- 108010068265 aspartyltyrosine Proteins 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000011545 carbonate/bicarbonate buffer Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- KBQHZAAAGSGFKK-UHFFFAOYSA-N dysprosium atom Chemical compound [Dy] KBQHZAAAGSGFKK-UHFFFAOYSA-N 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 description 1
- 108010066198 glycyl-leucyl-phenylalanine Proteins 0.000 description 1
- 108010089804 glycyl-threonine Proteins 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 108010025306 histidylleucine Proteins 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 108010078274 isoleucylvaline Proteins 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 108010003700 lysyl aspartic acid Proteins 0.000 description 1
- 108010054155 lysyllysine Proteins 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 108010063431 methionyl-aspartyl-glycine Proteins 0.000 description 1
- 108010056582 methionylglutamic acid Proteins 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000012803 optimization experiment Methods 0.000 description 1
- 108010012581 phenylalanylglutamate Proteins 0.000 description 1
- 108010051242 phenylalanylserine Proteins 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108010077112 prolyl-proline Proteins 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- KZUNJOHGWZRPMI-UHFFFAOYSA-N samarium atom Chemical compound [Sm] KZUNJOHGWZRPMI-UHFFFAOYSA-N 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- POECFFCNUXZPJT-UHFFFAOYSA-M sodium;carbonic acid;hydrogen carbonate Chemical compound [Na+].OC(O)=O.OC([O-])=O POECFFCNUXZPJT-UHFFFAOYSA-M 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical compound [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 description 1
- 108010061238 threonyl-glycine Proteins 0.000 description 1
- 108010071097 threonyl-lysyl-proline Proteins 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 108010051110 tyrosyl-lysine Proteins 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 108010073969 valyllysine Proteins 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
Abstract
The invention discloses a kind of aftosa diagnostic kit and its aftosa diagnostic antigens used.The antigen is R1), R2) or protein R3): R1) amino acid sequence be SEQ ID No.2 protein, R2) amino acid sequence is the 166-282 protein of SEQ ID No.2, R3) in R1) or R2) shown in protein c-terminus or/and having with R1) of obtaining of aminoterminal fusion tag albumen or R2) identical active soluble fusion protein.It is high with the antibody assay kit sensibility of above-mentioned diagnostic antigen preparation, accuracy is high, it is easy to operate, quick, it can be as identification aftosa wild virus infection and vaccine immunity antibody assay kit, this method is suitable for base's Veterinary office at different levels and Entry-Exit Inspection and Quarantine Bureau to the rapid, high volume selective mechanisms of aftosa wild virus infection serum antibody, provides important technical for the prevention and control and purification of aftosa.
Description
Technical field
The present invention relates to a kind of aftosa diagnostic kit and its aftosa diagnostic antigens used.
Background technique
Aftosa (Foot and Mouth Disease, FMD) is by foot and mouth disease virus (Foot and Mouth
Disease Virus, FMDV) caused by artiodactyl is acute, hot, high degree in contact infects sexually transmitted disease.It is prevented and treated in aftosa
Major measure in work is that susceptible animal is immunized with inactivated foot-and-mouth disease vaccine.But this measure while also counterpart hoof
Animal is immunized in epidemic disease and infection animal antidiastole brings difficulty.Therefore, carry out the antidiastole technical research of aftosa pre-
Prevent, control, put out and purify the disease to have very important significance.Virus isolation techniques are the gold marks of diagnosis FMD as defined in OIE
Standard, although this method is more accurate, the time for needing to expend about several days could obtain as a result, and operating technology it is complicated, it is raw
Object safety requirements is high, is not suitable for base animal doctor quick diagnosis demand.Reverse transcription PCR and real-time quantitative PCR are widely used for
Detect FMDV.But both methods needs professional to carry out in the laboratory of profession, also diagnoses FMD to base testing staff
Bring certain difficulty.At present for the serological diagnostic method of FMDV wild virus infection, most commonly used is base
In the elisa technique of FMDV non-structural protein (Non Structure Protein) 3ABC.But 3ABC albumen is due to itself
The factors such as amino acid structure feature and sequence are longer, eukaryotic system expression is more difficult, and albumen is essentially after prokaryotic expression
Inclusion body structure.Because the expression product in inclusion body does not have biological activity, thus carries out denaturation and renaturation process.
The denaturation of albumen and renaturation are an extremely complex processes, and the denaturing conditions of different albumen are different, and renaturation yield is often difficult to mention
It is high.This is the active main restricting factor of limited antigen.
Summary of the invention
A technical problem to be solved by this invention is how to improve the spirit of the serology antibody test of foot and mouth disease virus
Sensitivity, and reduce omission factor and false positive rate, thus it is sensitiveer, more accurately diagnose aftosa.
In order to solve the above-mentioned technical problems, the present invention provides protein to prepare the application in antigen.
Protein provided by the present invention in preparing the application in antigen, the antigen can for aftosa diagnostic antigen or
Detect the antigen of mouth disease virus infection antibody, the protein can be R1), R2) or protein R3):
R1) amino acid sequence is the protein of SEQ ID No.2,
R2) amino acid sequence is the 166-282 protein of SEQ ID No.2,
R3) in R1) or R2) shown in protein c-terminus or/and aminoterminal fusion tag albumen obtain have with
R1) or R2) identical active soluble fusion protein.
In above-mentioned application, the antigen can be the protein.
In above-mentioned application, the label protein (protein-tag) refers to using DNA extracorporeal recombination, with purpose egg
A kind of polypeptide or albumen of Bai Yiqi amalgamation and expression, in order to the expression of destination protein, detection, tracer and/or purifying.It is described
Label protein can be Flag label protein, His label protein, MBP label protein, HA label protein, myc label protein, GST mark
Sign albumen and/or SUMO label protein etc..
In above-mentioned application, R1) protein name be known as rtagP3AB1B2, R2) protein name be known as rP3AB1B2.SEQ
ID No.2 is made of 290 amino acid residues.
In above-mentioned application, the protein can be prepared according to the method included the following steps: make the coding of the protein
Gene is expressed to obtain the protein in biology, and the biology can be microorganism, plant or non-human animal.
In above-mentioned application, so that the encoding gene of the protein is carried out expression in biology may include by the protein
Encoding gene imports recipient microorganism, obtains the recombinant microorganism for expressing the protein, cultivates the recombinant microorganism, expresses
Obtain the protein.
Any one of in above-mentioned application, the recipient microorganism can be C1)-C4):
C1) prokaryotic micro-organisms,
C2) gramnegative bacterium,
C3) Escherichia bacteria,
C4) e. coli bl21 (DE3).
In above-mentioned application, the encoding gene of the protein can be following 1) -4) in any DNA molecular:
1) coded sequence is the DNA molecular of SEQ ID No.1,
2) nucleotide sequence is the DNA molecular of SEQ ID No.1,
3) coded sequence is the DNA molecular of the 496-846 nucleotide of SEQ ID No.1,
4) nucleotide sequence is the DNA molecular of the 496-846 nucleotide of SEQ ID No.1.
In above-mentioned application, the recombinant microorganism can obtain for pET32a-3AB1B2 is imported e. coli bl21 (DE3)
Express amino acid sequence be SEQ ID No.2 protein recombinant microorganism, the recombinant microorganism is named as BL21
(DE3) it is 490-852 of SEQ ID No.1 that/pET32a-3AB1B2, the pET32a-3AB1B2, which are with nucleotide sequence,
DNA replacement pET32a (+) BamH I and XhoI recognition site between segment, keep pET32a (+) other sequences it is constant,
Obtained recombinant expression carrier.
In above-mentioned application, the expression can be inducing expression.
In above-mentioned application, the inducing expression be with the IPTG of 0.75mM 16 DEG C induction 13-16 hours or 13 hours.
In order to solve the above-mentioned technical problem, the present invention also provides a kind of kits.
Kit provided by the present invention be diagnose aftosa time-resolved fluoroimmunoassay (TRFIA) kit or
The time-resolved fluoroimmunoassay kit of antibodies against foot-and-mouth disease virus is detected, the kit includes envelope antigen, the packet
It is above-mentioned protein by antigen.
The kit further includes other reagents needed for carrying out time-resolved fluoroimmunoassay, as rare earth element marks
Secondary antibody.
The rare earth element can be europium (Eu3+), dysprosium (De3+), terbium (Te3+), samarium (Sm3+).
Application of the mentioned reagent box in preparation aftosa monitoring reagent box also belongs to protection scope of the present invention.
The present invention links together nonstructural protein 3A segment, 3B1 and the 3B2 of FMDV by link peptide to obtain fusion egg
RP3AB1B2 gene is inserted between BamH I and the XhoI recognition site of pET32a (+) and obtains to express by white rP3AB1B2
The recombinant expression carrier pET32a-3AB1B2 of fusion protein rtagP3AB1B2, imports Escherichia coli for pET32a-3AB1B2
The rtagP3AB1B2 of BL21 (DE3) acquisition solubility expression.It is diagnosed as a purpose with the rtagP3AB1B2 of solubility expression anti-
Non-structural protein antibody in former and/or detection antigen detection serum can be used to distinguish vaccine immunity animal and wild virus infection is dynamic
Object;Secondly non-structural protein is regardless of serotype, with rtagP3AB1B2 diagnostic antigen and/or the inspection as a purpose of solubility expression
The ELISA and time-resolved fluoroimmunoassay for surveying the non-structural protein antibody in the detection serum that antigen is established can be with counterparts
Seven kinds of serotypes of fever aphthous are detected.
Not only solubility expression ratio is high by rtagP3AB1B2 of the invention, but also compared with 3ABC holoantigen, detection it is quick
Perceptual suitable, specificity is more preferable, and accuracy is higher:
1, the present invention accounts for the 62% of bacterial protein using the rtagP3AB1B2 of Bacillus coli expression, and 95% is solvable.This
The rtag3AB1B2 for the soluble-expression that invention is obtained using Escherichia coli identifies aftosa wild virus infection and epidemic disease for further exploitation
Seedling immune antiboidy detection kit has established extraordinary basis.
2, the time-resolved fluoroimmunoassay detection mouth for establishing the rtag3AB1B2 of soluble-expression as envelope antigen
The time-resolved fluoroimmunoassay that the sensibility and rtag3ABC of aphtovirus antibody method are established as envelope antigen detects
The sensibility of antibodies against foot-and-mouth disease virus method is suitable, but is apparently higher than using rtag3B1B2, rtagP3A and rtag3A conduct
The sensibility for the time-resolved fluoroimmunoassay detection foot and mouth disease virus antibody method that envelope antigen is established, is also apparently higher than auspicious
The sensibility of scholar's PRIONICS aftosa NS antibody assay kit.
3, the time-resolved fluoroimmunoassay detection mouth for establishing the rtag3AB1B2 of soluble-expression as envelope antigen
The method of aphtovirus antibody and total coincidence rate of Switzerland PRIONICS aftosa NS antibody assay kit are significantly higher than difference
The time-resolved fluoroimmunoassay inspection established using rtag3ABC, rtag3B1B2, rtagP3A and rtag3A as envelope antigen
The method for surveying antibodies against foot-and-mouth disease virus.
The present invention is tried by the antibody test of diagnostic antigen and/or detection antigen preparation of the rtagP3AB1B2 of soluble-expression
Agent box sensibility is high, and accuracy is high, easy to operate, quick, is suitable for base's Veterinary office at different levels and Entry-Exit Inspection and Quarantine Bureau
To the rapid, high volume selective mechanisms of aftosa wild virus infection serum antibody, important technology hand is provided for the prevention and control and purification of aftosa
Section.
Detailed description of the invention
Fig. 1 is the SDS-PAGE electrophoresis spectrum that each bacterial strain expresses albumen.
In figure, swimming lane Marker be protein molecular weight standard, from top to bottom respectively 90kDa, 65kDa, 50kDa,
38kDa, 26kDa, 15kDa, 10kDa, 1 is BL21 (DE3)/pET30a whole bacterial protein liquid of inducing expression, and 2 be inducing expression
BL21 (DE3)/pET32a-3AB1B2 whole bacterial protein liquid, 3 be inducing expression BL21 (DE3)/pET32a-3AB1B2
Contain albumen precipitation containing albumen supernatant, 4 for BL21 (DE3)/pET32a-3AB1B2 of inducing expression, 5 be the BL21 of inducing expression
(DE3)/pET32a-3ABC whole bacterial protein liquid, 6 be BL21 (DE3)/pET32a-3ABC supernatant containing albumen of inducing expression
Liquid, 7 for inducing expression BL21 (DE3)/pET32a-3ABC contain albumen precipitation, 8 for inducing expression BL21 (DE3)/
The whole bacterial protein liquid of pET32a-3B1B2,9 for inducing expression BL21 (DE3)/pET32a-3B1B2 contain albumen supernatant, 10
Contain albumen precipitation for BL21 (DE3)/pET32a-3B1B2 of inducing expression, 11 be BL21 (DE3)/pET32a- of inducing expression
The whole bacterial protein liquid of P3A, 12 contain albumen supernatant for BL21 (DE3)/pET32a-P3A of inducing expression, and 13 be inducing expression
BL21 (DE3)/pET32a-P3A contain albumen precipitation, 14 be inducing expression BL21 (DE3)/pET32a-3A whole bacterial protein
Liquid, 15 for inducing expression BL21 (DE3)/pET32a-3A contain albumen supernatant, 16 for inducing expression BL21 (DE3)/
PET32a-3A contains albumen precipitation, and 17 be the rtagP3AB1B2 albumen of ni-sepharose purification, and 18 be the rtagP3AB1B2 of molecular sieve purification
Albumen.
The molecular sieve purification identification and Structural Identification that Fig. 2 is recombinant protein rtagP3AB1B2.Arrow meaning is purifying
Destination protein peak, the entitled retention volume (liter) for retaining purification column of abscissa.
Specific embodiment
The present invention is further described in detail With reference to embodiment, and the embodiment provided is only for explaining
The bright present invention, the range being not intended to be limiting of the invention.Examples provided below can be used as the art ordinary skill
The guide that personnel are further improved, is not construed as limiting the invention in any way.
Experimental method in following embodiments is unless otherwise specified conventional method.Material as used in the following examples
Material, reagent etc., are commercially available unless otherwise specified.
PET32a (+) in following embodiments is Novagen Products.Europium labelled element (Eu3+) is Guangzhou Da Ruisheng
Object technical concern Co., Ltd product.Rabbit-anti goat secondary antibody is Sigma Products.Auto-DELFIA1235 time resolution is glimmering
Optical detector is purchased from PerkinElmer limited liability company.ELISA Plate is purchased from U.S. Costar company.In following embodiments
Switzerland PRIONICS aftosa NS antibody assay kit isFMDV NS Antibody ELISA test Kit
(FMDV NS FMDV Antibody test Kit, ELISA), lot number is F161101L, and article No. is
7610770。
Sheep FMDV non-structural protein Positive Sera in following embodiments is clinical sheep blood serum through Switzerland PRIONICS
The serum of aftosa NS antibody assay kit test positive, sheep FMDV non-structural protein negative antibody serum are clinical sheep blood
Negative serum is detected as through Switzerland PRIONICS aftosa NS antibody assay kit clearly.
The solubility expression of embodiment 1, foot and mouth disease virus recombinant protein r3AB1B2 and rtag3AB1B2
1, the building of recombinant expression carrier
The building of 1.1 foot and mouth disease virus recombinant protein gene recombinant vectors
1.1.1 the design of foot and mouth disease virus recombinant protein gene
The application devises 5 kinds of foot and mouth disease virus recombinant protein genes, is shown in SEQ ID No.1 respectively
Rtag3ABC gene (crt gene 1) shown in rtagP3AB1B2 gene, SEQ ID No.3, shown in SEQ ID No.5
RtagP3A gene (crt gene 3) shown in rtag3B1B2 gene (crt gene 2), SEQ ID No.7 and SEQ ID No.9
Shown in rtag3A gene (crt gene 4).
1.1.1.1rtagP3AB1B2 gene (gene of the present invention)
SEQ ID No.1 is made of 873 nucleotide, wherein the 1-873 CDS for rtagP3AB1B2 gene, the
The 496-846 nucleotide sequences for rP3AB1B2 gene, 1-495 and the 847-873 sequences for pET32a (+),
The gene order (1-120 of GenBank:AY614501.1) of the 496-615 3A protein fragments for foot and mouth disease virus,
The gene order (430-498 of GenBank:AY614501.1) of the 661-729 3B1 albumen for foot and mouth disease virus,
The gene order (499-570 of GenBank:AY614501.1) of the 775-846 3B2 albumen for foot and mouth disease virus.
1.1.1.2rtag3ABC gene (foot and mouth disease virus overall length 3ABC genetic contrast)
SEQ ID No.3 is made of 1803 nucleotide, wherein the 1-1803 CDS for rtag3ABC gene, the
The 496-1776 nucleotide sequences (sequence with GenBank:AY614501.1 1-1281) for 3ABC gene, 1-
The 495 and 1777-1803 sequences for pET32a (+), the gene sequence of the 496-924 3A albumen for foot and mouth disease virus
It arranges (1-429 of GenBank:AY614501.1), the gene order of the 925-993 3B1 albumen for foot and mouth disease virus
(430-498 of GenBank:AY614501.1), the gene order of the 994-1065 3B2 albumen for foot and mouth disease virus
(499-570 of GenBank:AY614501.1), the gene sequence of the 1066-1137 3B3 albumen for foot and mouth disease virus
It arranges (571-642 of GenBank:AY614501.1), the gene sequence of the 1138-1776 3C albumen for foot and mouth disease virus
It arranges (643-1281 of GenBank:AY614501.1).
1.1.1.3rtag3B1B2 gene (foot and mouth disease virus 3B13B2 genetic contrast)
SEQ ID No.5 is made of 708 nucleotide, wherein the 1-708 CDS for rtag3B1B2 gene, the
The 496-681 nucleotide sequences for 3B1B2 gene, 1-495 and the 682-708 sequences for pET32a (+), the
The gene order (430-498 of GenBank:AY614501.1) of the 496-564 3B1 albumen for foot and mouth disease virus, the
The gene order (499-570 of GenBank:AY614501.1) of the 610-681 3B2 albumen for foot and mouth disease virus.
1.1.1.4rtagP3A gene (control of foot and mouth disease virus 3A fragment gene)
SEQ ID No.7 is made of 642 nucleotide, wherein the 1-642 CDS, 496- for rtagP3A gene
The gene order (1-120 of GenBank:AY614501.1) of 615 3A protein fragments for foot and mouth disease virus, 1-
The 495 and 616-642 sequences for pET32a (+).
1.1.1.5rtag3A gene (control of foot and mouth disease virus 3A full-length gene)
SEQ ID No.9 is made of 951 nucleotide, wherein the 1-951 CDS, 496- for rtag3A gene
The gene order (1-429 of GenBank:AY614501.1) of the 924 3A albumen for foot and mouth disease virus, 1-495
It is the sequence of pET32a (+) with 925-951.
1.1.2 the building of recombinant expression carrier
1.1.2.1rtagP3AB1B2 the building of gene recombinant vectors (expression vector of the invention)
With nucleotide sequence be SEQ ID No.1 490-852 DNA replacement pET32a (+) BamH I and
Segment (small fragment including BamH I recognition site and XhoI recognition site) between XhoI recognition site keeps pET32a
Other sequences of (+) are constant, obtain rtagP3AB1B2 gene recombinant vectors, are named as pET32a-3AB1B2.pET32a-
3AB1B2 contains the DNA molecular that nucleotide sequence is SEQ ID No.1.PET32a-3AB1B2 contains rtagP3AB1B2 gene,
The nucleotide sequence of rtagP3AB1B2 gene is SEQ ID No.1, and coded sequence is the 1-873 nucleosides of SEQ ID No.1
Acid, rtagP3AB1B2 gene encode protein rtagP3AB1B2 shown in SEQ ID No.2.
1.1.2.2rtag3ABC gene recombinant vectors (control of foot and mouth disease virus overall length 3ABC expression vector)
With nucleotide sequence be SEQ ID No.3 490-1782 DNA replacement pET32a (+) BamH I and
Segment (small fragment including BamH I recognition site and XhoI recognition site) between XhoI recognition site keeps pET32a
Other sequences of (+) are constant, obtain rtag3ABC gene recombinant vectors, are named as pET32a-3ABC.pET32a-3ABC
It is the DNA molecular of SEQ ID No.3 containing nucleotide sequence.PET32a-3ABC contains rtag3ABC gene, rtag3ABC gene
Nucleotide sequence be SEQ ID No.3, coded sequence is the 1-1803 nucleotide of SEQ ID No.3, rtag3ABC base
Because of protein rtag3ABC shown in coding SEQ ID No.4.
1.1.2.3rtag3B1B2 gene recombinant vectors (control of foot and mouth disease virus 3B13B2 expression vector)
With nucleotide sequence be SEQ ID No.5 490-687 DNA replacement pET32a (+) BamH I and
Segment (small fragment including BamH I recognition site and XhoI recognition site) between XhoI recognition site keeps pET32a
Other sequences of (+) are constant, obtain rtag3B1B2 gene recombinant vectors, are named as pET32a-3B1B2.pET32a-
3B1B2 contains the DNA molecular that nucleotide sequence is SEQ ID No.5.PET32a-3B1B2 contains rtag3B1B2 gene,
The nucleotide sequence of rtag3B1B2 gene is SEQ ID No.5, and coded sequence is the 1-708 nucleosides of SEQ ID No.5
Acid, rtag3B1B2 gene encode protein rtag3B1B2 shown in SEQ ID No.6.
1.1.2.4rtagP3A gene recombinant vectors (control of foot and mouth disease virus 3A fragment gene expression vector)
With nucleotide sequence be SEQ ID No.7 490-621 DNA replacement pET32a (+) BamH I and
Segment (small fragment including BamH I recognition site and XhoI recognition site) between XhoI recognition site keeps pET32a
Other sequences of (+) are constant, obtain rtagP3A gene recombinant vectors, are named as pET32a-P3A.PET32a-P3A contains
Nucleotide sequence is the DNA molecular of SEQ ID No.7.PET32a-P3A contains rtagP3A gene, the nucleosides of rtagP3A gene
Acid sequence is SEQ ID No.7, and coded sequence is the 1-642 nucleotide of SEQ ID No.7, and rtagP3A gene encodes SEQ
Protein rtagP3A shown in ID No.8.
1.1.2.5rtag3A gene recombinant vectors (control of foot and mouth disease virus 3A full-length gene expression vector)
With nucleotide sequence be SEQ ID No.9 490-930 DNA replacement pET32a (+) BamH I and
Segment (small fragment including BamH I recognition site and XhoI recognition site) between XhoI recognition site keeps pET32a
Other sequences of (+) are constant, obtain rtag3A gene recombinant vectors, are named as pET32a-3A.PET32a-3A contains core
Nucleotide sequence is the DNA molecular of SEQ ID No.9.PET32a-3A contains rtag3A gene, the nucleotide sequence of rtag3A gene
It is SEQ ID No.9, coded sequence is the 1-951 nucleotide of SEQ ID No.9, and rtag3A gene encodes SEQ ID
Protein rtag3A shown in No.10.
2, the building of recombinant bacterium
PET32a-3AB1B2, pET32a-3ABC that step 1 is constructed, pET32a-3B1B2, pET32a-P3A,
This 5 kinds of expression vectors of pET32a-3A individually convert e. coli bl21 (DE3) competent cell.It is spread evenly across
On LB plate containing ampicillin (50 μ g/mL), 37 DEG C are cultivated 16 hours.Single colonie shaken cultivation stay overnight, extract plasmid into
Row sequencing, shows that the recombination bacillus coli containing pET32a-3AB1B2 is named as BL21 (DE3)/pET32a- for sequencing result
Sequencing result is shown that the recombination bacillus coli containing pET32a-3ABC is named as BL21 (DE3)/pET32a- by 3AB1B2
Sequencing result is shown that the recombination bacillus coli containing pET32a-3B1B2 is named as BL21 (DE3)/pET32a- by 3ABC
Sequencing result is shown that the recombination bacillus coli containing pET32a-P3A is named as BL21 (DE3)/pET32a-P3A by 3B1B2, will
Sequencing result shows that the recombination bacillus coli containing pET32a-3A is named as BL21 (DE3)/pET32a-3A.Simultaneously by pET32a
(+) import e. coli bl21 (DE3) obtain being named as containing the recombination bacillus coli of pET32a (+) BL21 (DE3)/
PET32a, as empty vector control.
3, the analysis and identification of protein expression form
By BL21 (DE3)/pET32a-3AB1B2, BL21 (DE3)/pET32a-3ABC, BL21 (DE3)/pET32a-
This 6 bacterial strain difference of 3B1B2, BL21 (DE3)/pET32a-P3A, BL21 (DE3)/pET32a-3A and BL21 (DE3)/pET32a
It is individually inoculated in the LB liquid medium containing 50 μ g/ml ampicillins and (ampicillin is added extremely in LB liquid medium
The concentration of ampicillin is the obtained culture medium of 50 μ g/ml) in, 37 DEG C, using Thermo MaxQ6000 type warm oscillator entirely
200rpm shaken cultivation is to 0D600Value (using the LB liquid medium containing 50 μ g/ml ampicillins as blank control) reaches 0.6
When, isopropylthio-β-D-galactoside (IPTG) is added and carries out inducing expression.The inducing expression of above-mentioned 6 plants of bacterium is to use
The IPTG of 0.75mM 16 DEG C induce 13 hours (the inducing expression condition be by the conditions such as temperature, time, IPTG concentration into
The highly-soluble inducing expression condition that row optimization obtains).
Take above-mentioned inducing expression fermentation liquid for protein expression form analysis.The specific steps are take 1m L fermentation liquid to be placed in
It in 1.5mL centrifuge tube, marks, 8500rpm/min is centrifuged 45min under the conditions of 4 DEG C, discards supernatant, collects bacterial sediment.
1m L PBS is added, precipitating is resuspended, 8000rpm/min is centrifuged 5min, discards supernatant.It is added into the bacterial sediment washed
200 μ L PBS, high pressure are crushed thallus, and cracking is no longer sticky to bacterium solution, obtains whole bacterial protein liquid.By whole bacterial protein liquid in 4
18000rpm/min is centrifuged 45min in DEG C centrifuge, collects supernatant (being named as containing albumen supernatant) respectively and precipitating (is named
For containing albumen precipitation), 50 μ L PBS resuspension washing precipitating is added in albumen precipitation to containing.To whole bacterial protein liquid, containing on albumen
Clear liquid and containing 10 μ L 5 × SDS-PAGE loading Buffer are added in albumen precipitation, after mixing well, sets in boiling water bath and boils
Boil 5min, after sample is cooling, with hand held centrifuge wink from.Take 6 μ L for SDS-PAGE electrophoretic analysis, and binding protein is grey
Degree analysis software preliminary analysis protein content.Gel after electrophoresis is needed on NC film, the sheep anti-mouse antibody with anti-His label is
Binding antibody DAB colour developing, carries out Western-blot identification.By above-mentioned whole bacterial protein liquid and containing albumen supernatant with 0.22 μm
After membrane filtration loading in advance with solution 1 (solute and its concentration are as follows: 20mM Tris, 150mM NaCl, and solvent is water,
The solution of pH8.0) nickel column that has balanced.Nickel column is accessed on AKTA machine, respectively with solution 1 and 10 column of 10 column volumes
(solute and its concentration are as follows: 20mM Tris, 150mM NaCl, 50mM imidazoles, and solvent is water, and pH8.0's is molten for the solution 2 of volume
Liquid) impurity protein in cleaning nickel column, and protein peak is monitored on AKTA machine.With solution 3 (solute and its concentration are as follows:
20mM Tris, 150mM NaCl, 300mM imidazoles, solvent are water, the solution of pH8.0) destination protein hung in nickel column is rinsed,
And the elution samples for destination protein peak occur are collected using AKTA, which is known as ni-sepharose purification destination protein sample.
The Superdex200 gel column that the destination protein sample of ni-sepharose purification GE company is produced passes through molecular sieve into one
Step purifying.Mobile phase uses solution 1.By can remove a large amount of imidazoles contained in sample after molecular sieve purification, collection is washed
De- peak, obtains the destination protein sample of molecular sieve purification, right using NanoDrop2000 ultramicrospectrophotometer (ND2000)
The content of albumen (i.e. soluble destination protein) carries out quantitative analysis in the destination protein sample of obtained molecular sieve purification.It is used in combination
NanoDrop2000 ultramicrospectrophotometer (ND2000) measures the protein content in whole bacterial protein liquid, and it is total to obtain thallus
Protein content.It will contain after albumen precipitation dissolves with urea, be measured with NanoDrop2000 ultramicrospectrophotometer (ND2000)
Content containing the protein in albumen precipitation.
3.1BL21 (DE3)/pET32a-3AB1B2 expression
The result shows that BL21 (DE3)/pET32a-3AB1B2 whole bacterial protein liquid of inducing expression, contain albumen supernatant
With containing in albumen precipitation containing size be 31kDa destination protein rtagP3AB1B2;The BL21 (DE3) of inducing expression/
Destination protein rtagP3AB1B2 in the whole bacterial protein liquid of pET32a-3AB1B2 accounts for bacterial protein (full bacterium total protein)
62%, BL21 (DE3)/pET32a-3AB1B2 of inducing expression is accounted for containing the destination protein rtagP3AB1B2 in albumen supernatant
The 95% of destination protein rtagP3AB1B2 in BL21 (DE3)/pET32a-3AB1B2 whole bacterial protein liquid of inducing expression, should
95% destination protein rtagP3AB1B2 is soluble protein;BL21 (DE3)/pET32a-3AB1B2 of inducing expression contains egg
Destination protein rtagP3AB1B2 in white precipitating accounts for BL21 (DE3)/pET32a-3AB1B2 whole bacterial protein liquid of inducing expression
The 5% of destination protein rtagP3AB1B2 in body, the 5% destination protein rtagP3AB1B2 are insoluble inclusion body albumen;It says
BL21 (DE3)/pET32a-3AB1B2 destination protein rtagP3AB1B2 of bright inducing expression accounts for the 62% of bacterial protein,
95% is soluble protein in BL21 (DE3)/pET32a-3AB1B2 expression destination protein rtagP3AB1B2, and 5% is insoluble
Property inclusion body protein (Fig. 1).
3.2BL21 (DE3)/pET32a-3ABC expression
The result shows that BL21 (DE3)/pET32a-3ABC whole bacterial protein liquid of inducing expression and containing in albumen precipitation
The destination protein rtag3ABC for being 66kDa containing size, and BL21 (DE3)/pET32a-3ABC of inducing expression is containing on albumen
The destination protein rtag3ABC for being 66kDa without containing size in clear liquid.BL21 (DE3)/pET32a-3ABC of inducing expression is complete
Destination protein rtag3ABC in mycoprotein liquid accounts for the 17% of bacterial protein (full bacterium total protein).Illustrate BL21 (DE3)/
The destination protein rtag3ABC of pET32a-3ABC expression is insoluble inclusion body albumen, and BL21 (DE3)/pET32a-3ABC cannot
Express soluble destination protein (Fig. 1).
The expression of 3.3pET32a-3B1B2
The result shows that BL21 (DE3)/pET32a-3B1B2 whole bacterial protein liquid of inducing expression and contain albumen supernatant
In be 25kDa containing size destination protein rtag3B1B2, and BL21 (DE3)/pET32a-3B1B2 of inducing expression contains
The destination protein rtag3B1B2 for being 25kDa without containing size in albumen precipitation.BL21 (DE3)/pET32a- of inducing expression
Destination protein rtag3B1B2 in the whole bacterial protein liquid of 3B1B2 accounts for the 26% of bacterial protein (full bacterium total protein).Explanation
BL21 (DE3)/pET32a-3B1B2 expression destination protein rtag3B1B2 is soluble protein, BL21 (DE3)/pET32a-
3B1B2 cannot express inclusion body destination protein (Fig. 1).
3.4BL21 (DE3)/pET32a-P3A expression
The result shows that BL21 (DE3)/pET32a-P3A whole bacterial protein liquid of inducing expression and containing in albumen supernatant
The destination protein rtagP3A for being 23kDa containing size, and BL21 (DE3)/pET32a-P3A of inducing expression is heavy containing albumen
The destination protein rtagP3A for being 23kDa without containing size in shallow lake.The full bacterium egg of BL21 (DE3)/pET32a-P3A of inducing expression
Destination protein rtagP3A in white liquor body accounts for the 14% of bacterial protein (full bacterium total protein).Illustrate BL21 (DE3)/pET32a-
The destination protein rtagP3A of P3A expression is soluble protein, and BL21 (DE3)/pET32a-P3A cannot express inclusion body purpose egg
White (Fig. 1).
3.5BL21 (DE3)/pET32a-3A expression
The result shows that BL21 (DE3)/pET32a-3A whole bacterial protein liquid of inducing expression, containing albumen supernatant and containing
The destination protein rtag3A for being 35kDa containing size in albumen precipitation;BL21 (DE3)/pET32a-3A of inducing expression is complete
Destination protein rtag3A in mycoprotein liquid accounts for the 8% of bacterial protein (full bacterium total protein), the BL21 of inducing expression
(DE3)/pET32a-3A accounts for BL21 (DE3)/pET32a- of inducing expression containing the destination protein rtag3A in albumen supernatant
The 62% of destination protein rtag3A in the whole bacterial protein liquid of 3A, the 62% destination protein rtag3A are soluble protein;It lures
BL21 (the DE3)/pET32a-3A for leading expression accounts for the BL21 of inducing expression containing the destination protein rtag3A in albumen precipitation
(DE3) the 38% of destination protein rtag3A in/pET32a-3A whole bacterial protein liquid, the 38% destination protein rtag3A are
Insoluble inclusion body albumen;Illustrate that BL21 (DE3)/pET32a-3A destination protein rtag3A of inducing expression accounts for the total egg of thallus
62% is soluble protein in white 8%, BL21 (DE3)/pET32a-3A expression destination protein rtag3A, and 38% is insoluble
Property inclusion body protein (Fig. 1).
3.6 expression BL21 (DE3)/pET32a
The result shows that BL21 (DE3)/pET32a whole bacterial protein liquid of inducing expression does not have the expression of destination protein.
Although 3.1 and 3.2 result illustrates using same expression vector pET32a (+) and same host strain large intestine bar
The expression of bacterium BL21 (DE3), different external source target gene differ greatly, and rtagP3AB1B2 gene is passed through pET32a
(+), which imports e. coli bl21 (DE3), can get the solution expression with high efficiency of rtagP3AB1B2 gene, by rtag3ABC gene
It is imported in e. coli bl21 (DE3) by pET32a (+), rtag3ABC gene cannot but obtain solubility expression.
In addition, the present inventor research and develop the present invention during, by identical rP3AB1B2 encoding gene (SEQ
DNA molecular shown in 496-846 of ID No.1) insertion pET32a (+) EcoR I and XhoI recognition site between obtain
Recombinant prokaryotic expression vector does not express fusion protein but in e. coli bl21 (DE3).As it can be seen that by same foreign gene
It is inserted into the different location of same prokaryotic expression carrier, also will affect the expression of results of the foreign gene.
In addition, the present inventor research and develop the present invention during, by identical rP3AB1B2 encoding gene (SEQ
DNA molecular shown in 496-846 of ID No.1) it is inserted into the recombination obtained between the site Nde I and XhoI of pET30a (+)
Prokaryotic expression carrier, in e. coli bl21 (DE3) although in can obtain the destination protein of solubility expression, destination protein
Amount of soluble expression is very low, is mostly destination protein for inclusion body, the destination protein of solubility expression accounts for the destination protein of expression
The 27% of total amount.As it can be seen that same foreign gene to be inserted into different prokaryotic expression carriers, the expression of the foreign gene also will affect
As a result.
4, the solubility expression of rtagP3AB1B2 and purifying
BL21 (DE3)/pET32a-3AB1B2 is inoculated in the LB liquid medium containing 50 μ g/ml ampicillins (in LB
The concentration that ampicillin is added to ampicillin in fluid nutrient medium is the culture medium that 50 μ g/ml are obtained) in, it 37 DEG C, adopts
With Thermo MaxQ6000 type entirely warm oscillator 200rpm shaken cultivation to 0D600Value is (to contain the LB of 50 μ g/ml ampicillins
Fluid nutrient medium is blank control) when reaching 0.6, IPTG is added and carries out inducing expression.The IPTG of inducing expression 0.75mM
In 16 DEG C of induction 13h.Fermentation liquid after taking IPTG inducing expression 13h collects bacterial sediment.PBS is added, precipitating is resuspended,
8000rpm/min is centrifuged 5min, discards supernatant.PBS is added into the bacterial sediment washed, high pressure is crushed thallus, cracking
It is no longer sticky to bacterium solution, in 4 DEG C of centrifuges 16000rpm/min be centrifuged 30min, collect supernatant (be named as BL21 (DE3)/
PET32a-3AB1B2 contains albumen supernatant), abandon precipitating.BL21 (DE3)/pET32a-3AB1B2 is contained into albumen supernatant with 0.22
After μm membrane filtration loading in advance with solution 1 (solute and its concentration are as follows: 20mM Tris, 150mM NaCl, and solvent is water,
The solution of pH8.0) nickel column that has balanced.Nickel column is accessed on AKTA machine, respectively with solution 1 and 10 column of 10 column volumes
(solute and its concentration are as follows: 20mM Tris, 150mM NaCl, 50mM imidazoles, and solvent is water, and pH8.0's is molten for the solution 2 of volume
Liquid) impurity protein in cleaning nickel column, and protein peak is monitored on AKTA machine.With solution 3 (solute and its concentration are as follows:
20mM Tris, 150mM NaCl, 300mM imidazoles, solvent are water, the solution of pH8.0) rinse nickel column hang over the purpose in nickel column
Albumen, and the elution samples for destination protein peak occur are collected using AKTA, which is known as to the RtagP3AB1B2 of ni-sepharose purification
Albumen (ni-sepharose purification destination protein sample, Fig. 1 in swimming lane 17).
The Superdex200 gel column that the rtagP3AB1B2 albumen of ni-sepharose purification is produced with GE company is passed through into molecular sieve
It is further purified, obtains the rtagP3AB1B2 albumen (swimming lane 18 in Fig. 1) of molecular sieve purification.Flowing in the molecular sieve purification
Mutually use above-mentioned solution 1.By can remove a large amount of imidazoles contained in sample, rtagP3AB1B2 egg after molecular sieve purification
White structure is monomer structure (Fig. 2).The eluting peak for collecting monomer structure, obtains the rtagP3AB1B2 albumen of molecular sieve purification
(molecular sieve purification destination protein sample), using NanoDrop2000 ultramicrospectrophotometer (ND2000) to obtained albumen
Purity carry out quantitative analysis.
The rtagP3AB1B2 albumen of molecular sieve purification is analyzed by mass spectrometry its amino acid sequence, the results showed that
The amino acid sequence of rtagP3AB1B2 is as shown in SEQ ID No.2.
5, the expression and purifying of reference protein matter
5.1rtag3B1B2, solubility expression and the purifying of rtagP3A and rtag3A
Referring to the method for step 4, BL21 (DE3)/pET32a-3B1B2, BL21 (DE3)/pET32a-P3A, BL21 is utilized
(DE3)/pET32a-3A carries out inducing expression, respectively obtains the following reference protein matter (soluble protein) of molecular sieve purification:
Rtag3B1B2, rtagP3A and rtag3A.
5.2rtag3ABC expression and inclusion body be denaturalized renaturation
BL21 (DE3)/pET32a-3ABC that step 3 obtains is inoculated in the training of the LB liquid containing 50 μ g/ml ampicillins
Support in base, 37 DEG C, using Thermo MaxQ6000 type entirely warm oscillator 200rpm shaken cultivation to 0D600Value is (to contain 50 μ g/ml
The LB liquid medium of ampicillin is blank control) when reaching 0.6, IPTG is added and carries out inducing expression.The inducing expression
With the IPTG of 0.75mM in 16 DEG C of induction 13h.Fermentation liquid after taking IPTG inducing expression 13h collects bacterial sediment.PBS weight is added
Outstanding precipitating, 8000rpm/min are centrifuged 5min, discard supernatant.PBS is added into the bacterial sediment washed, high pressure is crushed bacterium
Body, cracking is no longer sticky to bacterium solution, and 16000rpm/min is centrifuged 30min in 4 DEG C of centrifuges, collects precipitating and (is named as BL21
(DE3)/pET32a-3ABC contains albumen precipitation), abandon supernatant.By BL21 (DE3)/pET32a-3ABC containing albumen precipitation with containing
The buffer (20mM Tris, 150mM NaCl, 8M urea, solvent are water, the solution of pH8.0) of the urea of 8M dissolves.Lysate
With loading after 0.22 μm of membrane filtration to solution 1, (solute and its concentration are as follows: 20mM Tris, 150mM NaCl, 8M in advance
Urea, solvent are water, the solution of pH8.0) nickel column that has balanced.Nickel column is accessed on AKTA machine, respectively with 10 column volumes
The solution 2 of solution 1 and 10 column volume (solute and its concentration are as follows: 20mM Tris, 150mM NaCl, 8M urea, 50mM
Imidazoles, solvent are water, the solution of pH8.0) impurity protein in cleaning nickel column, and protein peak is monitored on AKTA machine.With molten
(solute and its concentration are as follows: 20mM Tris, 150mM NaCl, 300mM imidazoles, 8M urea, and solvent is water, and pH8.0's is molten for liquid 3
Liquid) flushing nickel column hangs over the destination protein in nickel column, and the elution samples for destination protein peak occur are collected using AKTA, by the sample
Product are known as the rtag3ABC inclusion body protein of ni-sepharose purification.
Embodiment 2 detects aftosa by the time-resolved fluoroimmunoassay (TRFIA) of envelope antigen of rtag3AB1B2
Virus infection antibody
The antigen of aftosa diagnostic antigen provided by the present embodiment and detection mouth disease virus infection antibody is to implement
The rtag3AB1B2 albumen (hereinafter referred to as rtag3AB1B2 albumen) of the molecular sieve purification prepared in example 1.
It present embodiments provides and is tried by the time-resolved fluoroimmunoassay of the diagnosis aftosa of antigen of rtag3AB1B2
Agent box or the time-resolved fluoroimmunoassay kit for detecting antibodies against foot-and-mouth disease virus include envelope antigen, and envelope antigen is real
Apply the rtag3AB1B2 albumen (hereinafter referred to as rtag3AB1B2 albumen) of the molecular sieve purification prepared in example 1.
The time-resolved fluoroimmunoassay kit further includes that europium marks secondary antibody, coating buffer, cleaning solution, secondary antibody dilute
Release liquid.
The rabbit-anti goat secondary antibody (abbreviation europium marks secondary antibody) of europium label: Epstein-Barr virus core is prepared according to the method in following document
The south the development medical courses in general of antigen (NA1) IgA antibody and Zta protein I gA antibody time-resolved fluoroimmunoassay detection reagent are big
Learn 2012 grades of master thesis.
Be coated with buffer: the sodium carbonate-bicarbonate buffer (pH9.6) of 0.05mol/L, solvent is water, solute and its
Concentration is as follows: Na2CO31.59g/L and NaHCO3 2.93g/L。
Cleaning solution is PBST cleaning solution.PBST cleaning solution is prepared as follows: being 0.01M, pH value 7.4 in concentration
PBS buffer solution in be added polysorbas20 to polysorbas20 content be 5mL/L, obtain PBST cleaning solution.
Confining liquid is 1%BSA confining liquid.1%BSA confining liquid is prepared as follows: being 0.01M, pH value in concentration
1%BSA confining liquid is obtained until the volumn concentration of BSA is 1% for the BSA solution for adding 10% in 7.4 PBS buffer solution.
Secondary antibody diluent: being 0.01M in concentration, the content that BSA to BSA is added in the PBS buffer solution that pH value is 7.4 is
1% (volumn concentration), obtains secondary antibody diluent.
Wherein, concentration 0.01M, the preparation for the PBS buffer solution that pH value is 7.4: 8.5g NaCl, 0.2g KCl, 2.9g
Na2HPO4·12H2O、0.59g NaH2PO4·2H2O, 1L deionized water.
1, it establishes by optimization experiment using rtag3AB1B2 albumen as the time-resolved fluoroimmunoassay of envelope antigen
The optimization experimental method (hereinafter referred to as rtag3AB1B2 optimizes TRFIA method) that method detects antibodies against foot-and-mouth disease virus is as follows:
1.1 coatings: the rtag3AB1B2 albumen of molecular sieve purification in embodiment 1 is diluted (hereinafter referred to as with coating buffer
Rtag3AB1B2 albumen) to rtag3AB1B2 albumen concentration be 1.0 μ g/ml, obtain coating original solution, with the coating original solution
It is coated with experimental port, 100 holes μ L/ add to ELISA Plate, 4 DEG C of incubation 16h.
1.2 washings: incline hole endoperidium original solution, is washed 5 times with PBST cleaning solution, each 3min;It pats dry.
1.3 closings: 1%BSA confining liquid, 250 holes μ L/, 37 DEG C of incubation 2h are added.
1.4 sample-addings:
1.4.1 sample well
Sheep FMDV non-structural protein Positive Sera is diluted 50 times with coating buffer, obtains test serum.By 100
μ L test serum is added on ELISA Plate, 37 DEG C of reaction 1h, then liquid in hole of inclining is washed 5 times with cleaning solution.
1.4.2 blank control wells
Difference with 1.4.1, which is only that, replaces with test serum isometric high purity water, and other steps are constant.
1.5 add europium element mark secondary antibody: addition carries out the diluted europium of 1:50000 with secondary antibody diluent and marks rabbit-anti goat IgG,
100 holes μ L/, 37 DEG C of 30min.
1.6 colour developings: being added TMB, and 10min is reacted in 100 holes μ L/.
1.7 terminate: 0.2mol/L H is added2SO4Solution terminates reaction, 100 holes μ L/.
1.8 measurements: each hole fluorescence values are read with time-resolved fluorescence immunoassay instrument.
2, the determination of ELISA yin and yang attribute critical value
400 parts of sheep FMDV non-structural protein negative antibody serum are optimized into TRFIA method using the rtag3AB1B2 of step 1
(the sheep FMDV non-structural protein Positive Sera in 1.4.1 is replaced with into 400 parts of sheep FMDV non-structural protein antibody respectively
Negative serum, other operations are identical) TRFIA detection is carried out, calculate 400 parts of sheep FMDV non-structural protein negative antibody serum
Average value (X) and standard deviation (SD).It is judged to the positive; It is judged to feminine gender.
The result shows that 400 parts of sheep FMDV non-structural protein negative antibody serum Mean FluorescencesIt is for 1207, SD
114, therefore the critical fluorescent value of yin and yang attributeFor 1549.
3, specific test
Sheep perituberculosis positive serum, sheep cloth disease sun using the rtag3AB1B2 optimization TRFIA method of step 1 to each 10 parts
Property serum, peste des petits ruminants positive serum and clostridium perfringens disease positive serum detected, observation and Other diseases whether there is or not
Cross reaction.Wherein, the sheep FMDV non-structural protein Positive Sera in 1.4.1 is replaced with into above-mentioned serum respectively, it is other
It operates identical.The result shows that the rtag3AB1B2 optimize TRFIA method to sheep perituberculosis positive serum, sheep cloth disease positive serum,
Peste des petits ruminants positive serum and clostridium perfringens disease positive serum are detected, OD450Value is respectively as follows: 879,1220,
934,762, respectively less than critical value 1549 show rtag3AB1B2 and sheep perituberculosis positive serum, sheep cloth disease positive serum, small anti-
The rtag3AB1B2 of hay epizootic disease positive serum, the equal no cross reaction of clostridium perfringens disease positive serum, step 1 optimizes TRFIA
Method has good specificity.
4, sensitivity tests
Rtag3AB1B2 in the rtag3AB1B2 optimization TRFIA method of step 1 is replaced with into the other operations of rtag3ABC
It is constant, establish rtag3ABC optimization TRFIA method.
Rtag3AB1B2 in the rtag3AB1B2 optimization TRFIA method of step 1 is replaced with into rtag3B1B2, Qi Tacao
Make it is constant, establish rtag3B1B2 optimization TRFIA method.
Rtag3AB1B2 in the rtag3AB1B2 optimization TRFIA method of step 1 is replaced with into rtagP3A, other operations
It is constant, establish rtagP3A optimization TRFIA method.
Rtag3AB1B2 in the rtag3AB1B2 optimization TRFIA method of step 1 is replaced with into rtag3A, other operations are not
Become, establishes rtag3A optimization TRFIA method.
Sheep FMDV non-structural protein Positive Sera is subjected to doubling dilution, the rtag3AB1B2 of step 1 is respectively adopted
Optimize TRFIA method, rtag3ABC optimization TRFIA method, rtag3B1B2 optimization TRFIA method, rtagP3A and optimizes the side TRFIA
Method and rtag3A optimization TRFIA method are detected, and obtain greatest dilution when positive critical value.
The result shows that sheep FMDV non-structural protein Positive Sera is carried out doubling dilution since 1:4, using step 1
Rtag3AB1B2 optimization TRFIA method detection sheep FMDV non-structural protein Positive Sera dilution be 1: 2048 when still
It is positive;The sheep FMDV non-structural protein antibody sun detected using Switzerland PRIONICS aftosa NS antibody assay kit
Property serum greatest dilution be 1: 512;Using rtag3ABC optimization TRFIA method, rtag3B1B2 optimization TRFIA method,
Rtag3A optimization TRFIA method and rtagP3A optimization TRFIA method carry out detection sheep FMDV non-structural protein Positive Sera
Greatest dilution be respectively 1: 2048,1: 1024,1: 1024 and 1: 512.Show to build rtag3AB1B2 as envelope antigen
The sensibility and rtag3ABC of vertical time-resolved fluoroimmunoassay detection foot and mouth disease virus antibody method are as envelope antigen
The sensibility of the time-resolved fluoroimmunoassay detection foot and mouth disease virus antibody method of foundation is suitable, but is apparently higher than use
Rtag3B1B2, rtagP3A and rtag3A detect foot and mouth disease virus as the time-resolved fluoroimmunoassay that envelope antigen is established
The sensibility of antibody method is also apparently higher than the sensibility of Switzerland PRIONICS aftosa NS antibody assay kit.
5, repetitive test
Existed using the rtag3AB1B2 optimization TRFIA method of step 1 to 6 parts of sheep FMDV non-structural protein Positive Seras
It with being detected respectively on batch plate and different batches plate, is measured in parallel 5 times, calculates batch interior, interassay coefficient of variation (CV).As a result
Display repeats the coefficient of variation and repeats the coefficient of variation between 2%~8%, between batch less than 9% (table 1) in batch.The result shows that step
Rapid 1 rtag3AB1B2 optimization TRFIA method has good repeatability.
The rtag3AB1B2 of 1. step 1 of table optimizes TRFIA method repetitive test
6, accordance is tested
It is (agriculture from China Animal Disease Control And Prevention Center using Switzerland PRIONICS aftosa NS antibody assay kit
Rural area portion Disease Diagnosis of Veterinary center) save sheep blood serum picked out 90 parts of sheep FMDV non-structural protein Positive Seras and 90 parts
Sheep FMDV non-structural protein negative antibody serum.This 180 parts of sheep blood serums are respectively adopted with the rtag3AB1B2 optimization of step 1
TRFIA method, the rtag3ABC optimization TRFIA method of step 4, rtag3B1B2 optimization TRFIA method, rtagP3A optimization
TRFIA method and rtag3A optimization TRFIA method are detected, and are calculated and Switzerland PRIONICS aftosa NS antibody test reagent
The coincidence rate of box.
The result shows that 180 parts of sheep blood serums, the rtag3AB1B2 of step 1 optimizes TRFIA method and Switzerland PRIONICS mouthfuls
Total coincidence rate of fever aphthous NS antibody assay kit is that 96.11% (positive coincidence rate 97.78%, negative match-rate are
94.44%), the rtag3ABC optimization TRFIA method of step 4, rtag3B1B2 optimization TRFIA method, rtagP3A optimize TRFIA
Method and rtag3A optimization TRFIA method and total coincidence rate of Switzerland PRIONICS aftosa NS antibody assay kit are respectively
85% (positive coincidence rate 97.78%, negative match-rate 72.22%), 86.67% (positive coincidence rate 84.44%, yin
Property coincidence rate be 88.89%), 78.89% (positive coincidence rate 64.44%, negative match-rate 93.33%) and 76.11%
(positive coincidence rate 74.44%, negative match-rate 77.78%) (table 2- table 6).
Table 2.rtag3AB1B2 optimizes TRFIA method blood serum sample testing result
By 2 result of table, it can be concluded that, the rtag3AB1B2 of step 1 optimizes TRFIA method, detected 93 parts of positives,
87 parts of feminine genders.The sample that testing result is not consistent is 7 parts.The positive coincidence rate of two methods is 97.78%, and negative match-rate is
94.44%, total coincidence rate is 96.11% (being shown in Table 2).
Table 3.rtag3ABC optimizes TRFIA method blood serum sample testing result
By 3 result of table, it can be concluded that, the rtag3ABC of step 4 optimizes TRFIA method, detected 113 parts of positives, and 67
Part is negative.The sample that testing result is not consistent is 27 parts.The positive coincidence rate of two methods is 97.78%, and negative match-rate is
72.22%, total coincidence rate is 85% (being shown in Table 3).
Table 4.rtag3B1B2 optimizes TRFIA method blood serum sample testing result
By 4 result of table, it can be concluded that, the rtag3B1B2 of step 4 optimizes TRFIA method, detected 86 parts of positives, and 94
Part is negative.The sample that testing result is not consistent is 24 parts.The positive coincidence rate of two methods is 84.44%, and negative match-rate is
88.89%, total coincidence rate is 86.67% (being shown in Table 4).
Table 5.rtagP3A optimizes TRFIA method blood serum sample testing result
By 5 result of table, it can be concluded that, the rtagP3A of step 4 optimizes TRFIA method, detected 64 parts of positives, and 116
Part is negative.The sample that testing result is not consistent is 38 parts.The positive coincidence rate of two methods is 64.44%, and negative match-rate is
93.33%, total coincidence rate is 78.89% (being shown in Table 5).
Table 6.rtag3A optimizes TRFIA method blood serum sample testing result
By 6 result of table, it can be concluded that, the rtag3A of step 4 optimizes TRFIA method, detected 87 parts of positives, and 93 parts
It is negative.The sample that testing result is not consistent is 43 parts.The positive coincidence rate of two methods is 74.44%, and negative match-rate is
77.78%, total coincidence rate is 76.11% (being shown in Table 6).
Illustrate that the time-resolved fluoroimmunoassay for establishing rtag3AB1B2 as envelope antigen detects foot and mouth disease virus
The method of antibody and total coincidence rate of Switzerland PRIONICS aftosa NS antibody assay kit be significantly higher than respectively with
The time-resolved fluoroimmunoassay detection that rtag3ABC, rtag3B1B2, rtagP3A and rtag3A are established as envelope antigen
The method of antibodies against foot-and-mouth disease virus.
The present invention is had been described in detail above.To those skilled in the art, do not depart from spirit of the invention and
Range, and without carrying out under unnecessary experimental conditions, can synchronization parameters, concentration and under the conditions of, it is real in a wider range
Apply the present invention.Although The present invention gives particular embodiments, it is understood that, the present invention can be improved further.
In short, pressing the principle of the present invention, the application is intended to include any change, purposes or improvement of the present invention, including departing from this Shen
Please in the open scope, and the change carried out with routine techniques known in the art.By the range of following attached claims,
It can carry out the application of some essential characteristics.
Sequence table
<110>China Animal Disease Control And Prevention Center (technique center is butchered by the Ministry of Agriculture)
<120>a kind of aftosa diagnostic kit and its aftosa diagnostic antigen used
<130> GNCFH182287
<160> 10
<170> SIPOSequenceListing 1.0
<210> 1
<211> 873
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 1
atgagcgata aaattattca cctgactgac gacagttttg acacggatgt actcaaagcg 60
gacggggcga tcctcgtcga tttctgggca gagtggtgcg gtccgtgcaa aatgatcgcc 120
ccgattctgg atgaaatcgc tgacgaatat cagggcaaac tgaccgttgc aaaactgaac 180
atcgatcaaa accctggcac tgcgccgaaa tatggcatcc gtggtatccc gactctgctg 240
ctgttcaaaa acggtgaagt ggcggcaacc aaagtgggtg cactgtctaa aggtcagttg 300
aaagagttcc tcgacgctaa cctggccggt tctggttctg gccatatgca ccatcatcat 360
catcattctt ctggtctggt gccacgcggt tctggtatga aagaaaccgc tgctgctaaa 420
ttcgaacgcc agcacatgga cagcccagat ctgggtaccg acgacgacga caaggccatg 480
gctgatatcg gatccatttc aatcccttcc cagaaggctg tgttgtactt tctcattgag 540
aagggccagc acgaagcagc aattgagttc ttcgagggta tggtccacga ctccatcaag 600
gaggagctcc ggcctggtgg cggtggaatc ggaggtggtg gaagcggagg aggtggaagc 660
ggaccctacg ctgggccact cgagcgtcag aaacctctta aagtgaaagc caggctgcca 720
caacaggagg gtggcggtgg aatcggaggt ggtggaagcg gaggaggtgg aagcggaccc 780
tacgccggcc caatggagag acagaaacca ctaaaggtga aagcaaaagt ccccgtcgtg 840
aaggaactcg agcaccacca ccaccaccac tga 873
<210> 2
<211> 290
<212> PRT
<213>artificial sequence (Artificial Sequence)
<400> 2
Met Ser Asp Lys Ile Ile His Leu Thr Asp Asp Ser Phe Asp Thr Asp
1 5 10 15
Val Leu Lys Ala Asp Gly Ala Ile Leu Val Asp Phe Trp Ala Glu Trp
20 25 30
Cys Gly Pro Cys Lys Met Ile Ala Pro Ile Leu Asp Glu Ile Ala Asp
35 40 45
Glu Tyr Gln Gly Lys Leu Thr Val Ala Lys Leu Asn Ile Asp Gln Asn
50 55 60
Pro Gly Thr Ala Pro Lys Tyr Gly Ile Arg Gly Ile Pro Thr Leu Leu
65 70 75 80
Leu Phe Lys Asn Gly Glu Val Ala Ala Thr Lys Val Gly Ala Leu Ser
85 90 95
Lys Gly Gln Leu Lys Glu Phe Leu Asp Ala Asn Leu Ala Gly Ser Gly
100 105 110
Ser Gly His Met His His His His His His Ser Ser Gly Leu Val Pro
115 120 125
Arg Gly Ser Gly Met Lys Glu Thr Ala Ala Ala Lys Phe Glu Arg Gln
130 135 140
His Met Asp Ser Pro Asp Leu Gly Thr Asp Asp Asp Asp Lys Ala Met
145 150 155 160
Ala Asp Ile Gly Ser Ile Ser Ile Pro Ser Gln Lys Ala Val Leu Tyr
165 170 175
Phe Leu Ile Glu Lys Gly Gln His Glu Ala Ala Ile Glu Phe Phe Glu
180 185 190
Gly Met Val His Asp Ser Ile Lys Glu Glu Leu Arg Pro Gly Gly Gly
195 200 205
Gly Ile Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Pro Tyr Ala
210 215 220
Gly Pro Leu Glu Arg Gln Lys Pro Leu Lys Val Lys Ala Arg Leu Pro
225 230 235 240
Gln Gln Glu Gly Gly Gly Gly Ile Gly Gly Gly Gly Ser Gly Gly Gly
245 250 255
Gly Ser Gly Pro Tyr Ala Gly Pro Met Glu Arg Gln Lys Pro Leu Lys
260 265 270
Val Lys Ala Lys Val Pro Val Val Lys Glu Leu Glu His His His His
275 280 285
His His
290
<210> 3
<211> 1803
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 3
atgagcgata aaattattca cctgactgac gacagttttg acacggatgt actcaaagcg 60
gacggggcga tcctcgtcga tttctgggca gagtggtgcg gtccgtgcaa aatgatcgcc 120
ccgattctgg atgaaatcgc tgacgaatat cagggcaaac tgaccgttgc aaaactgaac 180
atcgatcaaa accctggcac tgcgccgaaa tatggcatcc gtggtatccc gactctgctg 240
ctgttcaaaa acggtgaagt ggcggcaacc aaagtgggtg cactgtctaa aggtcagttg 300
aaagagttcc tcgacgctaa cctggccggt tctggttctg gccatatgca ccatcatcat 360
catcattctt ctggtctggt gccacgcggt tctggtatga aagaaaccgc tgctgctaaa 420
ttcgaacgcc agcacatgga cagcccagat ctgggtaccg acgacgacga caaggccatg 480
gctgatatcg gatccatttc aatcccttcc cagaaggctg tgttgtactt tctcattgag 540
aagggccagc acgaagcagc aattgagttc ttcgagggta tggtccacga ctccatcaag 600
gaggagctcc ggcctctcat ccagcagacc tcgtttgtac aacgcgcctt caagcgcctg 660
aaggagaact ttgagattgt agctctgtgt ttaaccctct tggcaaacat agtgattatg 720
ctccgccaag cgcgcaagag acgccagtcg gtggatgacc cactggacgg cgacataact 780
cttggcgacg cggaaaagga ccctctggag gcgcgtggcg ctagcgctgt cggtttcaga 840
gagagaccac ccaccgagca agagacgtgc gaagacgcga acgctgagcc tgtcgtgctc 900
gggagggaac aaccgcgagc tgaaggaccc tacgctgggc cactcgagcg tcagaaacct 960
cttaaagtga aagccaggct gccacaacag gagggaccct acgccggccc aatggagaga 1020
cagaaaccac taaaggtgaa agcaaaagtc cccgtcgtga aggaaggacc ttacgaggga 1080
ccggtgaaga aacctgtcgc tttgaaagtg aaagcaaaga acttgatagt cactgagagt 1140
ggtgcgccac cgaccgactt gcaaaagatg gtcatgggca acactaagcc ggtcgagctt 1200
atcctcgacg gcaagacggt ggccatctgt tgtgccaccg gagtgtttgg cactgcctac 1260
ctcgtgcctc gtcacctctt cgcggagaag tatgacaaga tcatgttgga cggtagagcc 1320
ttaacagaca gcgactacag agtgttcgag tttgagatta aagtaaaagg acaggacatg 1380
ctctcagacg ccgctctcat ggtgttgcac cgtgggaacc gcgtgcgcga tatcacgaaa 1440
cactttcgtg atgtggcgag aatgaagaag ggaacccccg tcgtcggtgt gatcaacaat 1500
gctgacgtag ggagactcat attctctggt gaagccctta cttacaagga catcgtcgtg 1560
tgtatggacg gagacaccat gcctgggctc ttcgcctaca gagcgtccac caaggcaggc 1620
tactgtggag gagccgtcct cgcaaaggac ggtgccgaga cgttcatcgt tggcactcac 1680
tccgcaggtg gtaacggtat aggatactgc tcctgcgtct cccgatcgat gctcatgaag 1740
atgaaggcac acatcgaccc cgaaccacac cacgagctcg agcaccacca ccaccaccac 1800
tga 1803
<210> 4
<211> 600
<212> PRT
<213>artificial sequence (Artificial Sequence)
<400> 4
Met Ser Asp Lys Ile Ile His Leu Thr Asp Asp Ser Phe Asp Thr Asp
1 5 10 15
Val Leu Lys Ala Asp Gly Ala Ile Leu Val Asp Phe Trp Ala Glu Trp
20 25 30
Cys Gly Pro Cys Lys Met Ile Ala Pro Ile Leu Asp Glu Ile Ala Asp
35 40 45
Glu Tyr Gln Gly Lys Leu Thr Val Ala Lys Leu Asn Ile Asp Gln Asn
50 55 60
Pro Gly Thr Ala Pro Lys Tyr Gly Ile Arg Gly Ile Pro Thr Leu Leu
65 70 75 80
Leu Phe Lys Asn Gly Glu Val Ala Ala Thr Lys Val Gly Ala Leu Ser
85 90 95
Lys Gly Gln Leu Lys Glu Phe Leu Asp Ala Asn Leu Ala Gly Ser Gly
100 105 110
Ser Gly His Met His His His His His His Ser Ser Gly Leu Val Pro
115 120 125
Arg Gly Ser Gly Met Lys Glu Thr Ala Ala Ala Lys Phe Glu Arg Gln
130 135 140
His Met Asp Ser Pro Asp Leu Gly Thr Asp Asp Asp Asp Lys Ala Met
145 150 155 160
Ala Asp Ile Gly Ser Ile Ser Ile Pro Ser Gln Lys Ala Val Leu Tyr
165 170 175
Phe Leu Ile Glu Lys Gly Gln His Glu Ala Ala Ile Glu Phe Phe Glu
180 185 190
Gly Met Val His Asp Ser Ile Lys Glu Glu Leu Arg Pro Leu Ile Gln
195 200 205
Gln Thr Ser Phe Val Gln Arg Ala Phe Lys Arg Leu Lys Glu Asn Phe
210 215 220
Glu Ile Val Ala Leu Cys Leu Thr Leu Leu Ala Asn Ile Val Ile Met
225 230 235 240
Leu Arg Gln Ala Arg Lys Arg Arg Gln Ser Val Asp Asp Pro Leu Asp
245 250 255
Gly Asp Ile Thr Leu Gly Asp Ala Glu Lys Asp Pro Leu Glu Ala Arg
260 265 270
Gly Ala Ser Ala Val Gly Phe Arg Glu Arg Pro Pro Thr Glu Gln Glu
275 280 285
Thr Cys Glu Asp Ala Asn Ala Glu Pro Val Val Leu Gly Arg Glu Gln
290 295 300
Pro Arg Ala Glu Gly Pro Tyr Ala Gly Pro Leu Glu Arg Gln Lys Pro
305 310 315 320
Leu Lys Val Lys Ala Arg Leu Pro Gln Gln Glu Gly Pro Tyr Ala Gly
325 330 335
Pro Met Glu Arg Gln Lys Pro Leu Lys Val Lys Ala Lys Val Pro Val
340 345 350
Val Lys Glu Gly Pro Tyr Glu Gly Pro Val Lys Lys Pro Val Ala Leu
355 360 365
Lys Val Lys Ala Lys Asn Leu Ile Val Thr Glu Ser Gly Ala Pro Pro
370 375 380
Thr Asp Leu Gln Lys Met Val Met Gly Asn Thr Lys Pro Val Glu Leu
385 390 395 400
Ile Leu Asp Gly Lys Thr Val Ala Ile Cys Cys Ala Thr Gly Val Phe
405 410 415
Gly Thr Ala Tyr Leu Val Pro Arg His Leu Phe Ala Glu Lys Tyr Asp
420 425 430
Lys Ile Met Leu Asp Gly Arg Ala Leu Thr Asp Ser Asp Tyr Arg Val
435 440 445
Phe Glu Phe Glu Ile Lys Val Lys Gly Gln Asp Met Leu Ser Asp Ala
450 455 460
Ala Leu Met Val Leu His Arg Gly Asn Arg Val Arg Asp Ile Thr Lys
465 470 475 480
His Phe Arg Asp Val Ala Arg Met Lys Lys Gly Thr Pro Val Val Gly
485 490 495
Val Ile Asn Asn Ala Asp Val Gly Arg Leu Ile Phe Ser Gly Glu Ala
500 505 510
Leu Thr Tyr Lys Asp Ile Val Val Cys Met Asp Gly Asp Thr Met Pro
515 520 525
Gly Leu Phe Ala Tyr Arg Ala Ser Thr Lys Ala Gly Tyr Cys Gly Gly
530 535 540
Ala Val Leu Ala Lys Asp Gly Ala Glu Thr Phe Ile Val Gly Thr His
545 550 555 560
Ser Ala Gly Gly Asn Gly Ile Gly Tyr Cys Ser Cys Val Ser Arg Ser
565 570 575
Met Leu Met Lys Met Lys Ala His Ile Asp Pro Glu Pro His His Glu
580 585 590
Leu Glu His His His His His His
595 600
<210> 5
<211> 708
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 5
atgagcgata aaattattca cctgactgac gacagttttg acacggatgt actcaaagcg 60
gacggggcga tcctcgtcga tttctgggca gagtggtgcg gtccgtgcaa aatgatcgcc 120
ccgattctgg atgaaatcgc tgacgaatat cagggcaaac tgaccgttgc aaaactgaac 180
atcgatcaaa accctggcac tgcgccgaaa tatggcatcc gtggtatccc gactctgctg 240
ctgttcaaaa acggtgaagt ggcggcaacc aaagtgggtg cactgtctaa aggtcagttg 300
aaagagttcc tcgacgctaa cctggccggt tctggttctg gccatatgca ccatcatcat 360
catcattctt ctggtctggt gccacgcggt tctggtatga aagaaaccgc tgctgctaaa 420
ttcgaacgcc agcacatgga cagcccagat ctgggtaccg acgacgacga caaggccatg 480
gctgatatcg gatccggacc ctacgctggg ccactcgagc gtcagaaacc tcttaaagtg 540
aaagccaggc tgccacaaca ggagggtggc ggtggaatcg gaggtggtgg aagcggagga 600
ggtggaagcg gaccctacgc cggcccaatg gagagacaga aaccactaaa ggtgaaagca 660
aaagtccccg tcgtgaagga actcgagcac caccaccacc accactga 708
<210> 6
<211> 235
<212> PRT
<213>artificial sequence (Artificial Sequence)
<400> 6
Met Ser Asp Lys Ile Ile His Leu Thr Asp Asp Ser Phe Asp Thr Asp
1 5 10 15
Val Leu Lys Ala Asp Gly Ala Ile Leu Val Asp Phe Trp Ala Glu Trp
20 25 30
Cys Gly Pro Cys Lys Met Ile Ala Pro Ile Leu Asp Glu Ile Ala Asp
35 40 45
Glu Tyr Gln Gly Lys Leu Thr Val Ala Lys Leu Asn Ile Asp Gln Asn
50 55 60
Pro Gly Thr Ala Pro Lys Tyr Gly Ile Arg Gly Ile Pro Thr Leu Leu
65 70 75 80
Leu Phe Lys Asn Gly Glu Val Ala Ala Thr Lys Val Gly Ala Leu Ser
85 90 95
Lys Gly Gln Leu Lys Glu Phe Leu Asp Ala Asn Leu Ala Gly Ser Gly
100 105 110
Ser Gly His Met His His His His His His Ser Ser Gly Leu Val Pro
115 120 125
Arg Gly Ser Gly Met Lys Glu Thr Ala Ala Ala Lys Phe Glu Arg Gln
130 135 140
His Met Asp Ser Pro Asp Leu Gly Thr Asp Asp Asp Asp Lys Ala Met
145 150 155 160
Ala Asp Ile Gly Ser Gly Pro Tyr Ala Gly Pro Leu Glu Arg Gln Lys
165 170 175
Pro Leu Lys Val Lys Ala Arg Leu Pro Gln Gln Glu Gly Gly Gly Gly
180 185 190
Ile Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Pro Tyr Ala Gly
195 200 205
Pro Met Glu Arg Gln Lys Pro Leu Lys Val Lys Ala Lys Val Pro Val
210 215 220
Val Lys Glu Leu Glu His His His His His His
225 230 235
<210> 7
<211> 642
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 7
atgagcgata aaattattca cctgactgac gacagttttg acacggatgt actcaaagcg 60
gacggggcga tcctcgtcga tttctgggca gagtggtgcg gtccgtgcaa aatgatcgcc 120
ccgattctgg atgaaatcgc tgacgaatat cagggcaaac tgaccgttgc aaaactgaac 180
atcgatcaaa accctggcac tgcgccgaaa tatggcatcc gtggtatccc gactctgctg 240
ctgttcaaaa acggtgaagt ggcggcaacc aaagtgggtg cactgtctaa aggtcagttg 300
aaagagttcc tcgacgctaa cctggccggt tctggttctg gccatatgca ccatcatcat 360
catcattctt ctggtctggt gccacgcggt tctggtatga aagaaaccgc tgctgctaaa 420
ttcgaacgcc agcacatgga cagcccagat ctgggtaccg acgacgacga caaggccatg 480
gctgatatcg gatccatttc aatcccttcc cagaaggctg tgttgtactt tctcattgag 540
aagggccagc acgaagcagc aattgagttc ttcgagggta tggtccacga ctccatcaag 600
gaggagctcc ggcctctcga gcaccaccac caccaccact ga 642
<210> 8
<211> 213
<212> PRT
<213>artificial sequence (Artificial Sequence)
<400> 8
Met Ser Asp Lys Ile Ile His Leu Thr Asp Asp Ser Phe Asp Thr Asp
1 5 10 15
Val Leu Lys Ala Asp Gly Ala Ile Leu Val Asp Phe Trp Ala Glu Trp
20 25 30
Cys Gly Pro Cys Lys Met Ile Ala Pro Ile Leu Asp Glu Ile Ala Asp
35 40 45
Glu Tyr Gln Gly Lys Leu Thr Val Ala Lys Leu Asn Ile Asp Gln Asn
50 55 60
Pro Gly Thr Ala Pro Lys Tyr Gly Ile Arg Gly Ile Pro Thr Leu Leu
65 70 75 80
Leu Phe Lys Asn Gly Glu Val Ala Ala Thr Lys Val Gly Ala Leu Ser
85 90 95
Lys Gly Gln Leu Lys Glu Phe Leu Asp Ala Asn Leu Ala Gly Ser Gly
100 105 110
Ser Gly His Met His His His His His His Ser Ser Gly Leu Val Pro
115 120 125
Arg Gly Ser Gly Met Lys Glu Thr Ala Ala Ala Lys Phe Glu Arg Gln
130 135 140
His Met Asp Ser Pro Asp Leu Gly Thr Asp Asp Asp Asp Lys Ala Met
145 150 155 160
Ala Asp Ile Gly Ser Ile Ser Ile Pro Ser Gln Lys Ala Val Leu Tyr
165 170 175
Phe Leu Ile Glu Lys Gly Gln His Glu Ala Ala Ile Glu Phe Phe Glu
180 185 190
Gly Met Val His Asp Ser Ile Lys Glu Glu Leu Arg Pro Leu Glu His
195 200 205
His His His His His
210
<210> 9
<211> 951
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 9
atgagcgata aaattattca cctgactgac gacagttttg acacggatgt actcaaagcg 60
gacggggcga tcctcgtcga tttctgggca gagtggtgcg gtccgtgcaa aatgatcgcc 120
ccgattctgg atgaaatcgc tgacgaatat cagggcaaac tgaccgttgc aaaactgaac 180
atcgatcaaa accctggcac tgcgccgaaa tatggcatcc gtggtatccc gactctgctg 240
ctgttcaaaa acggtgaagt ggcggcaacc aaagtgggtg cactgtctaa aggtcagttg 300
aaagagttcc tcgacgctaa cctggccggt tctggttctg gccatatgca ccatcatcat 360
catcattctt ctggtctggt gccacgcggt tctggtatga aagaaaccgc tgctgctaaa 420
ttcgaacgcc agcacatgga cagcccagat ctgggtaccg acgacgacga caaggccatg 480
gctgatatcg gatccatttc aatcccttcc cagaaggctg tgttgtactt tctcattgag 540
aagggccagc acgaagcagc aattgagttc ttcgagggta tggtccacga ctccatcaag 600
gaggagctcc ggcctctcat ccagcagacc tcgtttgtac aacgcgcctt caagcgcctg 660
aaggagaact ttgagattgt agctctgtgt ttaaccctct tggcaaacat agtgattatg 720
ctccgccaag cgcgcaagag acgccagtcg gtggatgacc cactggacgg cgacataact 780
cttggcgacg cggaaaagga ccctctggag gcgcgtggcg ctagcgctgt cggtttcaga 840
gagagaccac ccaccgagca agagacgtgc gaagacgcga acgctgagcc tgtcgtgctc 900
gggagggaac aaccgcgagc tgaactcgag caccaccacc accaccactg a 951
<210> 10
<211> 316
<212> PRT
<213>artificial sequence (Artificial Sequence)
<400> 10
Met Ser Asp Lys Ile Ile His Leu Thr Asp Asp Ser Phe Asp Thr Asp
1 5 10 15
Val Leu Lys Ala Asp Gly Ala Ile Leu Val Asp Phe Trp Ala Glu Trp
20 25 30
Cys Gly Pro Cys Lys Met Ile Ala Pro Ile Leu Asp Glu Ile Ala Asp
35 40 45
Glu Tyr Gln Gly Lys Leu Thr Val Ala Lys Leu Asn Ile Asp Gln Asn
50 55 60
Pro Gly Thr Ala Pro Lys Tyr Gly Ile Arg Gly Ile Pro Thr Leu Leu
65 70 75 80
Leu Phe Lys Asn Gly Glu Val Ala Ala Thr Lys Val Gly Ala Leu Ser
85 90 95
Lys Gly Gln Leu Lys Glu Phe Leu Asp Ala Asn Leu Ala Gly Ser Gly
100 105 110
Ser Gly His Met His His His His His His Ser Ser Gly Leu Val Pro
115 120 125
Arg Gly Ser Gly Met Lys Glu Thr Ala Ala Ala Lys Phe Glu Arg Gln
130 135 140
His Met Asp Ser Pro Asp Leu Gly Thr Asp Asp Asp Asp Lys Ala Met
145 150 155 160
Ala Asp Ile Gly Ser Ile Ser Ile Pro Ser Gln Lys Ala Val Leu Tyr
165 170 175
Phe Leu Ile Glu Lys Gly Gln His Glu Ala Ala Ile Glu Phe Phe Glu
180 185 190
Gly Met Val His Asp Ser Ile Lys Glu Glu Leu Arg Pro Leu Ile Gln
195 200 205
Gln Thr Ser Phe Val Gln Arg Ala Phe Lys Arg Leu Lys Glu Asn Phe
210 215 220
Glu Ile Val Ala Leu Cys Leu Thr Leu Leu Ala Asn Ile Val Ile Met
225 230 235 240
Leu Arg Gln Ala Arg Lys Arg Arg Gln Ser Val Asp Asp Pro Leu Asp
245 250 255
Gly Asp Ile Thr Leu Gly Asp Ala Glu Lys Asp Pro Leu Glu Ala Arg
260 265 270
Gly Ala Ser Ala Val Gly Phe Arg Glu Arg Pro Pro Thr Glu Gln Glu
275 280 285
Thr Cys Glu Asp Ala Asn Ala Glu Pro Val Val Leu Gly Arg Glu Gln
290 295 300
Pro Arg Ala Glu Leu Glu His His His His His His
305 310 315
Claims (10)
1. protein is preparing the application in antigen, it is characterised in that: the antigen is aftosa diagnostic antigen or detection mouth hoof
The antigen of epidemic disease virus infection antibody, the protein are R1), R2) or protein R3):
R1) amino acid sequence is the protein of SEQ ID No.2,
R2) amino acid sequence is the 166-282 protein of SEQ ID No.2,
R3) in R1) or R2) shown in protein c-terminus or/and having of obtaining of aminoterminal fusion tag albumen and R1) or
R2) identical active soluble fusion protein.
2. application according to claim 1, it is characterised in that: the protein is according to the method system included the following steps
It is standby: to make the encoding gene of the protein be expressed to obtain the protein in biology, the biology is microorganism, plant
Or non-human animal.
3. application according to claim 2, it is characterised in that: make the encoding gene of protein carry out table in biology
Up to including that the encoding gene of the protein is imported recipient microorganism, the recombinant microorganism for expressing the protein is obtained, is trained
The recombinant microorganism is supported, expression obtains the protein.
Any one of 4. application according to claim 3, it is characterised in that: the recipient microorganism is C1)-C4):
C1) prokaryotic micro-organisms,
C2) gramnegative bacterium,
C3) Escherichia bacteria,
C4) e. coli bl21 (DE3).
5. according to the application any in claim 2-4, it is characterised in that: the encoding gene of the protein is as follows
1) any DNA molecular in -4):
1) coded sequence is the DNA molecular of SEQ ID No.1,
2) nucleotide sequence is the DNA molecular of SEQ ID No.1,
3) coded sequence is the DNA molecular of the 496-846 nucleotide of SEQ ID No.1,
4) nucleotide sequence is the DNA molecular of the 496-846 nucleotide of SEQ ID No.1.
6. according to the application any in claim 3-5, it is characterised in that: the recombinant microorganism is by pET32a-
The recombination that 3AB1B2 imports the protein that the express amino acid sequence that e. coli bl21 (DE3) is obtained is SEQ ID No.2 is micro-
Biology, the recombinant microorganism are named as BL21 (DE3)/pET32a-3AB1B2, and the pET32a-3AB1B2 is to use nucleotide
Sequence is the piece between BamH I and the XhoI recognition site of 490-852 DNA replacement pET32a (+) of SEQ ID No.1
Section keeps other sequences of pET32a (+) constant, obtained recombinant expression carrier.
7. according to the application any in claim 2-6, it is characterised in that: described to be expressed as inducing expression.
8. application according to claim 7, it is characterised in that: the inducing expression is to be lured with the IPTG of 0.75mM at 16 DEG C
It leads 13-16 hours or 13 hours.
9. kit, it is characterised in that: the kit be diagnose aftosa time-resolved fluoroimmunoassay kit or
The time-resolved fluoroimmunoassay kit of antibodies against foot-and-mouth disease virus is detected, the kit includes envelope antigen, the packet
It is protein as claimed in any one of claims 1 to 6 by antigen.
10. application of the kit as claimed in claim 9 in preparation aftosa monitoring reagent box.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811580365.0A CN109851675B (en) | 2018-12-24 | 2018-12-24 | Foot-and-mouth disease diagnostic kit and foot-and-mouth disease diagnostic antigen used by same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811580365.0A CN109851675B (en) | 2018-12-24 | 2018-12-24 | Foot-and-mouth disease diagnostic kit and foot-and-mouth disease diagnostic antigen used by same |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109851675A true CN109851675A (en) | 2019-06-07 |
CN109851675B CN109851675B (en) | 2020-09-01 |
Family
ID=66892013
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811580365.0A Expired - Fee Related CN109851675B (en) | 2018-12-24 | 2018-12-24 | Foot-and-mouth disease diagnostic kit and foot-and-mouth disease diagnostic antigen used by same |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109851675B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109851662A (en) * | 2018-12-24 | 2019-06-07 | 中国动物疫病预防控制中心(农业部屠宰技术中心) | Foot and mouth disease virus recombinant protein and its relevant biological material and application |
CN114656572A (en) * | 2022-02-25 | 2022-06-24 | 北京大学第一医院 | BP180 antibody rapid detection kit and preparation method thereof |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1858062A (en) * | 2005-05-08 | 2006-11-08 | 上海市农业科学院畜牧兽医研究所 | Enzyme-linked immunosorbent test detecting reagent kit for non-structure protein of pig and cow foot and mouth disease virus |
CN103063838A (en) * | 2012-10-11 | 2013-04-24 | 广东出入境检验检疫局检验检疫技术中心 | Primer and kit for identifying foot-and-mouth disease and immunity of entry animal |
CN105388282A (en) * | 2015-10-22 | 2016-03-09 | 中国农业科学院兰州兽医研究所 | Coating method for indirect antigen-coated elisa plate of ELISA kit |
CN105418738A (en) * | 2015-07-03 | 2016-03-23 | 申联生物医药(上海)有限公司 | A-type antigen polypeptide, fusion antigen polypeptide and vaccine of foot and mouth disease virus |
US20170218053A1 (en) * | 2016-01-29 | 2017-08-03 | Alfonso Clavijo | Monoclonal antibody against novel epitopes of foot-and-mouth disease virus protein 3abc and uses thereof |
CN107201346A (en) * | 2017-03-22 | 2017-09-26 | 中国农业科学院兰州兽医研究所 | The strain of aftosa marker vaccine and its construction method and application of 3B albumen Dominant Epitopes missing |
CN109851662A (en) * | 2018-12-24 | 2019-06-07 | 中国动物疫病预防控制中心(农业部屠宰技术中心) | Foot and mouth disease virus recombinant protein and its relevant biological material and application |
-
2018
- 2018-12-24 CN CN201811580365.0A patent/CN109851675B/en not_active Expired - Fee Related
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1858062A (en) * | 2005-05-08 | 2006-11-08 | 上海市农业科学院畜牧兽医研究所 | Enzyme-linked immunosorbent test detecting reagent kit for non-structure protein of pig and cow foot and mouth disease virus |
CN103063838A (en) * | 2012-10-11 | 2013-04-24 | 广东出入境检验检疫局检验检疫技术中心 | Primer and kit for identifying foot-and-mouth disease and immunity of entry animal |
CN105418738A (en) * | 2015-07-03 | 2016-03-23 | 申联生物医药(上海)有限公司 | A-type antigen polypeptide, fusion antigen polypeptide and vaccine of foot and mouth disease virus |
CN105388282A (en) * | 2015-10-22 | 2016-03-09 | 中国农业科学院兰州兽医研究所 | Coating method for indirect antigen-coated elisa plate of ELISA kit |
US20170218053A1 (en) * | 2016-01-29 | 2017-08-03 | Alfonso Clavijo | Monoclonal antibody against novel epitopes of foot-and-mouth disease virus protein 3abc and uses thereof |
CN107201346A (en) * | 2017-03-22 | 2017-09-26 | 中国农业科学院兰州兽医研究所 | The strain of aftosa marker vaccine and its construction method and application of 3B albumen Dominant Epitopes missing |
CN109851662A (en) * | 2018-12-24 | 2019-06-07 | 中国动物疫病预防控制中心(农业部屠宰技术中心) | Foot and mouth disease virus recombinant protein and its relevant biological material and application |
Non-Patent Citations (5)
Title |
---|
JAJATI K. MOHAPATRA ET AL: "Recombinant non-structural polyprotein 3AB-based serodiagnostic strategy for FMD surveillance in bovines irrespective of vaccination", 《JOURNAL OF VIROLOGICAL METHODS》 * |
N. KUMAR ET AL: "Non-Structural Protein 3A for Differentiation of Foot-and-Mouth Disease Infected and Vaccinated Animals in Haryana (India)", 《ZOONOSES AND PUBLIC HEALTH》 * |
孙明等: "口蹄疫病毒非结构蛋白VPg1-2、VPg2-3、VPg3 基因的克隆、表达及VPg1-2 抗体持续时间的研究", 《中国农业科学》 * |
辛甜甜等: "时间分辨荧光免疫分析的新进展", 《理化检验-化学分册》 * |
龚振华等: "A蛋白间接ELISA试验检测猪口蹄疫感染抗体的研究", 《中国动物检疫》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109851662A (en) * | 2018-12-24 | 2019-06-07 | 中国动物疫病预防控制中心(农业部屠宰技术中心) | Foot and mouth disease virus recombinant protein and its relevant biological material and application |
CN109851662B (en) * | 2018-12-24 | 2020-09-01 | 中国动物疫病预防控制中心(农业部屠宰技术中心) | Foot-and-mouth disease virus recombinant protein and related biological material and application thereof |
CN114656572A (en) * | 2022-02-25 | 2022-06-24 | 北京大学第一医院 | BP180 antibody rapid detection kit and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
CN109851675B (en) | 2020-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107238702B (en) | Detect the enzyme linked immunological kit of PPR virus antibody | |
CN107894506B (en) | Detect enzyme linked immunological kit and its application of capripox virus antibody | |
CN107098979A (en) | PPR virus H F fusion proteins and its relevant biological material and application | |
CN110105436A (en) | The ELISA detection kit and the preparation method and application thereof of 3 type antibody of pig circular ring virus | |
CN102964435B (en) | Truncated-form streptococcus hemolyticus bacteriolysin O and detection kit using same | |
CN108627648A (en) | A kind of ELISA antibody assay kits of 3 type of novel pig circular ring virus and its application | |
CN109851675A (en) | A kind of aftosa diagnostic kit and its aftosa diagnostic antigen used | |
CN109856396A (en) | Detect enzyme linked immunological kit and its application of mouth disease virus infection antibody | |
CN107759674A (en) | A kind of Mycoplasma bovis immune-related albumen, the detection kit containing the albumen and its purposes in Mycoplasma bovis antibody test | |
CN108101995B (en) | Recombinant capripoxvirus fusion protein and application thereof | |
CN109425735A (en) | A kind of kit detecting pig sramana bacteria antibody | |
CN104761628A (en) | Babesia mocroti Bm7 recombinant antigenic protein, preparation method and purpose thereof | |
CN101982777B (en) | Duck plague virus antigen capturing ELISA method based on anti-recombination UL51 albumen antibody | |
CN109851662A (en) | Foot and mouth disease virus recombinant protein and its relevant biological material and application | |
CN108624713A (en) | A kind of porcine pseudorabies vaccine virus differentiates the method and kit of detection with wild poison | |
CN115073557A (en) | Recombinant high-purity African swine fever virus pK205R subunit protein and preparation method and application thereof | |
CN105330727B (en) | 1 type duck hepatitis A virus VP4 recombinant protein of one kind, ELISA kit and preparation method thereof | |
CN107236047A (en) | Recombinate the solubility expression method of PPR virus H F fusion proteins | |
CN102128936A (en) | ELISA (Enzyme Linked Immuno-Sorbent Assay) knit based on Nsp10 protein in PRRSV (porcine reproductive and respiratory syndrome virus) | |
CN110196325B (en) | In-plug virus diagnosis kit and test paper | |
CN109187952A (en) | One boar atypia pestivirus ELISA antibody assay kit | |
CN110229218B (en) | Reagent for detecting Seneca virus antibody and polypeptide used by same | |
CN103789442A (en) | Primer, probe and kit for detecting and typing rickettsia by virtue of real-time FRET-PCR (Fluorescent Resonance Energy Transfer-Polymerase Chain Reaction) and nested PCR | |
CN108164603B (en) | Soluble expression method of recombinant capripoxvirus fusion protein and biological material used by same | |
CN102993283B (en) | Antigen protein for mycobacterium tuberculosis and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20200901 |